



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 209/12, A61K 31/40, C07D 209/42, 401/12, 209/10, 405/12	A1	(11) International Publication Number: WO 98/08818 (43) International Publication Date: 5 March 1998 (05.03.98)
--	-----------	--

(21) International Application Number: PCT/US97/14943

(22) International Filing Date: 26 August 1997 (26.08.97)

(30) Priority Data:
08/703,115 26 August 1996 (26.08.96) US

(71) Applicant: GENETICS INSTITUTE, INC. [US/US]; 87 CambridgePark Drive, Cambridge, MA 02140 (US).

(72) Inventors: XIANG, YiBin; 821 Main Street, Acton, MA 01720 (US). BEMIS, Jean; 256 Appleton Street, Arlington, MA 02174 (US). MCKEW, John; 58 Varnum Street, Arlington, MA 02174 (US). KAILA, Neelu; 2 Course Brook Lane, Natick, MA 01760 (US).

(74) Agent: BROWN, Scott, A.; Genetics Institute, Inc., 87 CambridgePark Drive, Cambridge, MA 02140 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).


Published

With international search report.

(54) Title: INHIBITORS OF PHOSPHOLIPASE ENZYMES

(57) Abstract


Compounds having a chemical formula selected from the group consisting of formulae (I), (II) and (III) or a pharmaceutically acceptable salt thereof, wherein: A is independent of any other group and is selected from the group consisting of -CH₂- and -CH₂-CH₂-; B is independent of any other group and is selected from the group consisting of -(CH₂)_n-, -(CH₂O)_n-, -(CH₂S)_n-, -(OCH₂)_n-, -(SCH₂)_n-, -(CH=CH)_n-, -(C≡C)_n-, -CON(R₆)-, -N(R₆)CO-, -O-, -S- and -N(R₆)-; R₂ is independent of any other R group and is selected from the group consisting of -H, -COOH, -COR₅, -CONR₅R₆, -(CH₂)_n-W-(CH₂)_m-Z-R₅, -(CH₂)_n-W-R₅, -Z-R₅, C₁-C₁₀ alkyl, alkenyl and substituted aryl; R₃ is independent of any other R group and is selected from the group consisting of -H, -COOH, -COR₅, -CONR₅R₆, -(CH₂)_n-W-(CH₂)_m-Z-R₅, -(CH₂)_n-W-R₅, -Z-R₅, C₁-C₁₀ alkyl, alkenyl and substituted aryl; which inhibit the activity of phospholipase enzymes, particularly cytosolic phospholipase A₂. Pharmaceutical compositions comprising such compounds and methods of treatment using such compositions are also disclosed.



(I)



(II)



(III)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INHIBITORS OF PHOSPHOLIPASE ENZYMES

Background of the Invention

5 The present invention relates to chemical inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A₂ enzymes.

Leukotrienes and prostaglandins are important mediators of inflammation. Leukotrienes recruit inflammatory cells such as neutrophils to an inflamed site, promote the extravasation of these cells and stimulate release of superoxide and proteases which damage the tissue. Leukotrienes also play a pathophysiological role in the hypersensitivity
10 experienced by asthmatics [See, e.g. B. Samuelson et al., Science, 237:1171-76 (1987)]. Prostaglandins enhance inflammation by increasing blood flow and therefore infiltration of leukocytes to inflamed sites. Prostaglandins also potentiate the pain response induced by stimuli. Prostaglandins and leukotrienes are unstable and are not stored in cells, but are instead synthesized [W. L. Smith, Biochem. J., 259:315-324 (1989)] from arachidonic acid
15 in response to stimuli. Likewise arachidonic acid is not free in cells but is released from the sn-2 position of membrane phospholipids by phospholipase A₂ (hereinafter PLA₂). The reaction catalyzed by PLA₂ is believed to represent the rate-limiting step in the process of lipid mediated biosynthesis. When the phospholipid substrate of PLA₂ is of the phosphatidyl choline class with an ether linkage in the sn-1 position, the lysophospholipid
20 produced is the immediate precursor of platelet activating factor (hereafter called PAF), another potent mediator of inflammation [S.I. Wasserman, Hospital Practice, 15:49-58 (1988)]. Consequently the direct inhibition of the activity of PLA₂ has been suggested as a useful mechanism for a therapeutic agent, i.e., to interfere with the inflammatory response. [See, e.g., J. Chang et al, Biochem. Pharmacol., 36:2429-2436 (1987)].

25 A family of PLA₂ enzymes characterized by the presence of a secretion signal sequenced and ultimately secreted from the cell have been sequenced and structurally defined. These secreted PLA₂s have an approximately 14 kD molecular weight and contain seven disulfide bonds which are necessary for activity. These PLA₂s are found in large quantities in mammalian pancreas, bee venom, and various snake venom. [See, e.g.,
30 references 13-15 in Chang et al, cited above; and E. A. Dennis, Drug Devel. Res., 10:205-220 (1987).] However, the pancreatic enzyme is believed to serve a digestive function and, as such, should not be important in the production of the inflammatory mediators whose production must be tightly regulated.

The primary structure of the first human non-pancreatic PLA₂ has been determined.
35 This non-pancreatic PLA₂ is found in platelets, synovial fluid, and spleen and is also a

secreted enzyme. This enzyme is a member of the aforementioned family. [See, J. J. Seilhamer et al, J. Biol. Chem., 264:5335-5338 (1989); R. M. Kramer et al, J. Biol. Chem., 264:5768-5775 (1989); and A. Kando et al, Biochem. Biophys. Res. Comm., 163:42-48 (1989)]. However, it is doubtful that this enzyme is important in the synthesis of
5 prostaglandins, leukotrienes and PAF, since the non-pancreatic PLA₂ is an extracellular protein which would be difficult to regulate, and the next enzymes in the biosynthetic pathways for these compounds are intracellular proteins. Moreover, there is evidence that PLA₂ is regulated by protein kinase C and G proteins [R. Burch and J. Axelrod, Proc. Natl. Acad. Sci. U.S.A., 84:6374-6378 (1989)] which are cytosolic proteins which must act on
10 intracellular proteins. It would be impossible for the non-pancreatic PLA₂ to function in the cytosol, since the high reduction potential would reduce the disulfide bonds and inactivate the enzyme.

A murine PLA₂ has been identified in the murine macrophage cell line, designated RAW 264.7. A specific activity of 2 μmols/min/mg, resistant to reducing conditions, was
15 reported to be associated with the approximately 60 kD molecule. However, this protein was not purified to homogeneity. [See, C. C. Leslie et al, Biochem. Biophys. Acta., 963:476-492 (1988)]. The references cited above are incorporated by reference herein for information pertaining to the function of the phospholipase enzymes, particularly PLA₂.

A cytosolic phospholipase A₂ (hereinafter "cPLA₂") has also been identified and
20 cloned. See, U.S. Patent Nos. 5,322,776 and 5,354,677, which are incorporated herein by reference as if fully set forth. The enzyme of these patents is an intracellular PLA₂ enzyme, purified from its natural source or otherwise produced in purified form, which functions intracellularly to produce arachidonic acid in response to inflammatory stimuli.


Now that several phospholipase enzymes have been identified, it would be
25 desirable to identify chemical inhibitors of the action of enzymes, which inhibitors could be used to treat inflammatory conditions. However, there remains a need in the art for an identification of effective anti-inflammatory agents for therapeutic use in a variety of disease states.

30

Summary of the Invention


The present invention provides compounds having a chemical formula selected from the group consisting of:

5



10

and



15

or a pharmaceutically acceptable salt thereof, wherein:

A is independent of any other group and is selected from the group consisting of $-\text{CH}_2-$ and $-\text{CH}_2-\text{CH}_2-$;

20 B is independent of any other group and is selected from the group consisting of $-(\text{CH}_2)_n-$, $-(\text{CH}_2\text{O})_n-$, $-(\text{CH}_2\text{S})_n-$, $-(\text{OCH}_2)_n-$, $-(\text{SCH}_2)_n-$, $-(\text{CH}=\text{CH})_n-$, $-(\text{C}\equiv\text{C})_n-$, $-\text{CON}(\text{R}_6)-$, $-\text{N}(\text{R}_6)\text{CO}-$, $-\text{O}-$, $-\text{S}-$ and $-\text{N}(\text{R}_6)-$;


R_1 is independent of any other R group and is selected from the group consisting of $-\text{X}-\text{R}_6$, $-\text{H}$, $-\text{OH}$, halogen, $-\text{CN}$, $-\text{NO}_2$, C_1-C_5 alkyl, alkenyl, alkynyl, aryl and substituted aryl;

25 R_2 is independent of any other R group and is selected from the group consisting of $-\text{H}$, $-\text{COOH}$, $-\text{COR}_5$, $-\text{CONR}_5\text{R}_6$, $-(\text{CH}_2)_n-\text{W}-(\text{CH}_2)_m-\text{Z}-\text{R}_5$, $-(\text{CH}_2)_n-\text{W}-\text{R}_5$, $-\text{Z}-\text{R}_5$, C_1-C_{10} alkyl, alkenyl and substituted aryl;

R_3 is independent of any other R group and is selected from the group consisting of $-\text{H}$, $-\text{COOH}$, $-\text{COR}_5$, $-\text{CONR}_5\text{R}_6$, $-(\text{CH}_2)_n-\text{W}-(\text{CH}_2)_m-\text{Z}-\text{R}_5$, $-(\text{CH}_2)_n-\text{W}-\text{R}_5$, $-\text{Z}-\text{R}_5$, C_1-C_{10} alkyl, alkenyl and substituted aryl;

30 R_4 is independent of any other R group and is selected from the group consisting of $-\text{H}$, $-\text{OH}$, $-\text{OR}_6$, $-\text{SR}_6$, $-\text{CN}$, $-\text{COR}_6$, $-\text{NHR}_6$, $-\text{COOH}$, $-\text{CONR}_6\text{R}_7$, $-\text{NO}_2$, $-\text{CONHSO}_2\text{R}_8$, C_1-C_5 alkyl, alkenyl and substituted aryl;

35 R_5 is independent of any other R group and is selected from the group consisting of $-\text{H}$, $-\text{OH}$, $-\text{O}(\text{CH}_2)_n\text{R}_6$, $-\text{SR}_6$, $-\text{CN}$, $-\text{COR}_6$, $-\text{NHR}_6$, $-\text{COOH}$, $-\text{NO}_2$, $-\text{COOH}$, $-\text{CONR}_6\text{R}_7$, $-\text{CONHSO}_2\text{R}_8$, C_1-C_5 alkyl, alkenyl, alkynyl, aryl, substituted aryl, $-\text{CF}_3$, $-\text{CF}_2\text{CF}_3$ and



5 R_6 is independent of any other R group and is selected from the group consisting of -H, C_1-C_5 alkyl, alkenyl, alkynyl, aryl and substituted aryl;

R_7 is independent of any other R group and is selected from the group consisting of -H, C_1-C_5 alkyl, alkenyl, alkynyl, aryl and substituted aryl;

10 R_8 is independent of any other R group and is selected from the group consisting of C_1-C_3 alkyl, aryl and substituted aryl;

R_9 is independent of any other R group and is selected from the group consisting of -H, -OH, a halogen, -CN, -OR₆, -COOH, -CONR₆R₇, tetrazole, -CONHSO₂R₈, -COR₆, -(CH₂)_nCH(OH)R₆ and -(CH₂)_nCHR₆R₅;

15 R_{10} is independent of any other R group and is selected from the group consisting of -H, -OH, a halogen, -CN, -OR₆, -COOH, -CONR₆R₇, tetrazole, -CONHSO₂R₈, -COR₆, -(CH₂)_nCH(OH)R₆ and -(CH₂)_nCHR₆R₅;

W is, independently each time used including within the same compound, selected from the group consisting of -O-, -S-, -CH₂-, -CH=CH-, -C≡C- and -N(R₆)-

20 X is independent of any other group and is, independently each time used including within the same compound, selected from the group consisting of -O-, -S- and -N(R₆)-


Z is independent of any other group and is, independently each time used including within the same compound, selected from the group consisting of -CH₂-, -O-, -S-, -N(R₆)-, -CO-, -CON(R₆)- and -N(R₆)CO-

25 m is, independently each time used including within the same compound, an integer from 0 to 4; and

n is independent of m and is, independently each time used including within the same compound, an integer from 0 to 4.

Preferably, the compounds of the invention have phospholipase enzyme inhibiting activity. Other preferred embodiments include compounds having the following chemical formula:


30



35


compounds having the following chemical formula:

5



compounds having the following chemical formula:

10



15

In particularly preferred embodiments, A is $-\text{CH}_2-$ and R_2 is $-(\text{CH}_2)_n-\text{W}-(\text{CH}_2)_m-\text{ZR}_5$. These preferred compounds includes those wherein n is 1, m is 1, W is $-\text{S}-$ and Z is $-\text{CO}-$; those wherein R_5 is $-\text{NHR}_6$; those wherein R_6 is a substituted aryl group and those wherein said aryl group is substituted with one or more substituents independently selected from the group consisting of a halogen, $-\text{CF}_3$,

20

$-\text{CF}_2\text{CF}_3$, $-(\text{CH}_2)_p\text{COOH}$, $-(\text{CH}_2)_p\text{CH}_3$, $-\text{O}(\text{CH}_2)_p\text{CH}_3$, $-(\text{CH}_2)_p\text{OH}$, $-(\text{CH}_2)_p\text{S}(\text{C}_6\text{H}_5)$, $-(\text{CH}_2)_p\text{CONH}_2$ and $-\text{CHR}_{11}\text{COOH}$, wherein R_{11} is selected from the group consisting of alkyl, alkenyl, alkynyl, $-(\text{CH}_2)_p\text{OH}$, and $-\text{O}(\text{CH}_2)_p\text{CH}_3$, and wherein p is an integer from 0 to 4. Other preferred compounds include those wherein R_1 is selected from the group consisting of $-\text{H}$ and $-\text{OCH}_2(\text{C}_6\text{H}_5)$ and R_3 is $-\text{COR}_4$, R_5 is $-\text{OCH}_2\text{R}_6$ and R_6 is a substituted aryl group. In particularly preferred compounds, said aryl group is substituted with one or more substituents selected from the group consisting of $-\text{CF}_3$, $-\text{CF}_2\text{CF}_3$ and $-\text{C}(\text{CH}_3)_2\text{CH}_2\text{CH}_3$.

25

30

The present invention also provides for a method of inhibiting the phospholipase enzyme activity of an enzyme, comprising administering to a mammalian subject a therapeutically effective amount of a compound of the present invention. Methods of treating an inflammatory condition, comprising administering to a mammalian subject a therapeutically effective amount of a compound of the present invention are also provided. Pharmaceutical compositions comprising compounds of the present invention and a pharmaceutically acceptable carrier are also provided.

Pharmaceutically acceptable salts of the compounds of the compounds described herein are also part of the present invention and may be used in practicing the compounds and methods disclosed herein.

5 Brief Description of the Figures

Figs. 1-13 depict schemes for synthesis of compounds of the present invention. The depicted schemes are described in further detail below.

Detailed Description of Preferred Embodiments






10 As used herein: "halogen" includes chlorine, fluorine, iodine and bromine; "alkyl", "alkenyl" and "alkinyl" include both straight chain and branched moieties; "aryl" includes single and multiple ring moieties; and "substituted" denotes the presence of one or more similar or dissimilar substituent groups of any character.





Preferred compounds of the present invention are disclosed in Tables I-VI below.



15 Methods for synthesis of the compounds listed in Tables I-VI are described below. Compound Nos. in the tables correspond to example numbers below describing synthesis of that particular compound.

20 Tables I-VI also report data for the listed compounds in the "LysoPC" assay and the Coumarine assay (see Example 88 below). In the data columns of the tables, assay results are reported as an "IC₅₀" value, which is the concentration of a compound which inhibits 50% of the activity of the phospholipase enzyme in such assay. Where no numerical IC₅₀ value appears, "NA" denotes that inhibitory activity was not detected from such compound in the corresponding assay and a blank box denotes that the compound was not tested in such assay as of the time of filing of the present application.





Table I




				IC ₅₀ (μM)		
No.	R ₁	R ₂	R ₃	R ₄	Lyso	Cou-marine
1			-H		47	
2					6	

14		52	6
6.5	NA	4.3	2.0
			

		
--	---	---

3	4	5	6
---	---	---	---

15	2.1		3.8	0.11		6.5	0.081		28	0.33	
----	-----	---	-----	------	---	-----	-------	---	----	------	---

		
---	---	---

7	8	9	10
---	---	---	----

[illegible]

SUBSTITUTE SHEET (RULE 26)










15	16		
			
			
6.5	13	6.5	50





Table II

No.	R ₁	R ₂	IC ₅₀ (μM)	
			Lyso	Cou-marine
17			0.32	6






	0.28	10
	0.21	4
	0.28	9
	0.29	4.5




18	19	20	21
----	----	----	----

	0.10	5
	0.95	5
	1.6	2.5
	1.3	10




22	23	24	25
----	----	----	----

18	1.2	
13	2.3	
--	--	

26	27	28
----	----	----

	28	44
		

29	30	31
----	----	----

	3.8	5
	2.6	5
	24	>50

32	33	34
----	----	----









35			9.1	28
36	-H		2.3	4

Table III

		No.	R	IC ₅₀ (μM)	
				Lyso PC	Cou-marine
		37	-OH	7.6	>30
		38			

18	11	22	14
4.3	6.2	2.2	7.8
			
39	40	41	42






43		7.1	21
----	---	-----	----

Table IV

No.	R	IC ₅₀ (μM)	
		Lyso PC	Cou-marine
44	H-	27	>30

45		0.37	5
46		0.71	10
47		1.6	16
48		0.3	5.5
49	CH ₃ -	40	>50















50		4.4	>50
----	---	-----	-----

Table V




			R_1	R_2	IC_{50} (μM)	
					Lyso PC	Cou-marine
No.						
51			36			
52			8.0	26		
53			15	>64		



14	12	5
0.23	0.45	0.47

		
54	55	56

8	4	>30	>30
0.26	0.56	8.7	4.6
			
			
57	58	59	60

12.1	1.7	
>20	8	

61		
62		
63		

64				17.6	>64
65	$\text{CH}_3(\text{CH}_2)_3\text{O}-$				
66				2.3	6
67				0.22	10
68				>50	>50
69				19.4	6














70		0.84	19
71		5.9	12






Table VI





		R ₁	R ₂	R ₃	IC ₅₀ (μM)	
					Lyso PC	Cou-marine
	No.					
	72					>64
	73				1.9	6



1.1	5
7.0	6.2
	4.5
	2.5
	3



74	75	76	77	78
----	----	----	----	----

4.2	16	15	15
		3.2	0.1
			
			
79	80	81	82

83	H-			>50	>50
				>50	23
				>50	21
84					
85					

17	6.5	
86	87	

Compounds of the present invention were also tested for *in vivo* activity in a rat paw edema test according to the procedure described in Example 89. The results are reported in Table VII.

5 Table VII

Compound No.	% inhibition of rat carrageenan-induced footpad edema
8	29
10	8.9
14	34.2
15	21.8
16	26.3
17	29.3
19	10.5
20	19.5
25	17.5
26	10.3
32	26.7
33	4.2
46	12.5
47	7.8
50	11.7
67	17.5
70	21.7
76	8.2
77	13.0

As used herein, "phospholipase enzyme activity" means positive activity in an assay for metabolism of phospholipids (preferably one of the assays described in Example 88 below). A compound has "phospholipase enzyme inhibiting activity" when it inhibits the activity of a phospholipase (preferably cPLA₂) in any available assay (preferably an

assay described below in Example 88 or Example 89) for enzyme activity. In preferred embodiments, a compound has (1) an IC_{50} value of less than about 25 μM , preferably less than about 6 μM , in the LysoPC assay; (2) an IC_{50} value of less than about 50 μM in the vesicle assay; (3) an IC_{50} value of less than about 1 μM in the PMN assay; (4) an IC_{50} value
5 of less than about 15 μM in the Coumarine assay; and/or (5) measurable activity (preferably at least about 5% reduction in edema, more preferably at least about 10% reduction) in the rat carrageenan-induced footpad edema test.

Compounds of the present invention are useful for inhibiting phospholipase enzyme (preferably $cPLA_2$) activity and, therefore, are useful in "treating" (i.e., treating,
10 preventing or ameliorating) inflammatory or inflammation-related conditions (e.g., rheumatoid arthritis, psoriasis, asthma, inflammatory bowel disease, and other diseases mediated by prostaglandins, leukotrienes or PAF) and other conditions, such as osteoporosis, colitis, myelogenous leukemia, diabetes, wasting and atherosclerosis.

The present invention encompasses both pharmaceutical compositions and
15 therapeutic methods of treatment or use which employ compounds of the present invention.

Compounds of the present invention may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable carrier. Such a composition may also contain (in addition to a compound or compounds of the present invention and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in
20 the art. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration. The pharmaceutical composition may further contain other anti-inflammatory agents. Such additional factors and/or agents may be included in the pharmaceutical composition to
25 produce a synergistic effect with compounds of the present invention, or to minimize side effects caused by the compound of the present invention.

The pharmaceutical composition of the invention may be in the form of a liposome in which compounds of the present invention are combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in
30 aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Patent No. 4,235,871; U.S. Patent No. 4,501,728;

U.S. Patent No. 4,837,028; and U.S. Patent No. 4,737,323, all of which are incorporated herein by reference.

As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of an inflammatory response or condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

In practicing the method of treatment or use of the present invention, a therapeutically effective amount of a compound of the present invention is administered to a mammal having a condition to be treated. Compounds of the present invention may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing other anti-inflammatory agents, cytokines, lymphokines or other hematopoietic factors. When co-administered with one or more other anti-inflammatory agents, cytokines, lymphokines or other hematopoietic factors, compounds of the present invention may be administered either simultaneously with the other anti-inflammatory agent(s), cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering compounds of the present invention in combination with other anti-inflammatory agent(s), cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.

Administration of compounds of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, or cutaneous, subcutaneous, or intravenous injection.

When a therapeutically effective amount of compounds of the present invention is administered orally, compounds of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% compound of the present invention, and preferably from about 25 to 90% compound of the present invention. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal

or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid
5 form, the pharmaceutical composition contains from about 0.5 to 90% by weight of compound of the present invention, and preferably from about 1 to 50% compound of the present invention.

When a therapeutically effective amount of compounds of the present invention is administered by intravenous, cutaneous or subcutaneous injection, compounds of the
10 present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to compounds of the present invention, an isotonic vehicle such as
15 Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.

The amount of compound(s) of the present invention in the pharmaceutical
20 composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of compound of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of compound of the present invention and observe the
25 patient's response. Larger doses of compounds of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.1 μ g to about 100 mg of compound of the present invention per kg body weight.

30 The duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the compounds of the present invention will be in the range of 12 to 24 hours of continuous intravenous administration. Ultimately the

attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.

Methods of Synthesis

- 5 Compounds of the present invention can be prepared according to the following methods. Temperatures are in degrees Celsius.

METHOD A

- 10 Indol-2-carboxylic acid ethyl ester I is converted to aldehyde II in two steps: reduction with lithium aluminum hydride (LAH) or other hydride in a suitable solvent such as tetrahydrofuran (THF) at 0 °C, and then oxidation with an oxidizing reagent such as manganese dioxide in a solvent such as THF. Deprotonation of aldehyde II with a strong base such as potassium hexamethyldisilyl amide (KHMDs) in THF, followed by reaction with a chloroformate in the presence of a base, such as triethyl amine, produces carbamate
- 15 III. III is transformed into bromide IV in two steps: (1) reduction with sodium borohydride in an alcoholic solution and (2) reaction with carbon tetrabromide in the presence of a phosphine reagent such as bis(diphenylphosphino)propane in dichloromethane. Displacement of the bromine in IV with potassium phenoxide, prepared by reaction of a phenol with KHMDs, in a suitable solvent such as THF or DMF affords ether V. V can be
- 20 converted to either trifluoromethyl ketone VII or to carboxylic acid IX in different procedures. Reaction of V with trifluoromethyl trimethylsilane (TMS-CF₃) in the presence of tetrabutylammonium fluoride gives trifluoromethyl alcohol, which is then oxidized with periodinane (Dess-Martin reagent) in dichloromethane to afford ketone VI. In this stage the carbamate can be removed with either trifluoroacetic acid (TFA) or with a base such as
- 25 sodium hydroxide. The indole nitrogen is then alkylated with a suitable alkyl bromide in the presence of a base such as sodium hydride to produce VII. Alternatively, V can be deprotected with TFA or aqueous base, and then reacted with alkyl bromide to give VIII, which is oxidized with sodium chlorite in an aqueous THF to yield acid IX.

30

METHOD B

2-Indolyl carboxylic acid ethyl ester I is deprotonated with a strong base such as sodium hydride (NaH) in THF, and then reacted with a suitable alkyl bromide to give X.

Hydrolysis of X with a aqueous base such as sodium hydroxide and reaction with aniline or a substituted aniline in the presence of a carbodiimide such as dimethylaminopropyl ethylcarbodiimide hydrochloride (EDCI) in a suitable solvent such as dichloromethane affords amide XI. XI is hydrolyzed to corresponding acid XII in a aqueous base such as sodium hydroxide.

METHOD C

Indole I can be brominated on the 3-position by reaction with a bromine or N-bromosuccinimide in a suitable solvent such as carbon tetrachloride or dichloromethane to yield bromide XIII. Reaction of XIII with a suitable alkyl bromide in the presence of a strong base such as NaH in THF or DMF affords indole XIV. Palladium mediated coupling of XIV with a suitable alkene in the presence of phosphine and a base such as triethyl amine produces 3-substituted indole XV. XV can be converted to amide XVII in two step reactions: (1) hydrolysis with aqueous base such as NaOH and (2) coupling with an amine in the presence of carbodiimide such as EDCI. Ester XIV can be transformed to lithium salt XVIII by hydrolysis with aqueous base and then reaction with lithium hydroxide in a suitable solvent such as ether. Lithiation with n-butyl lithium in a suitable solvent such as THF, and then acylation with an acyl chloride in THF affords ketone XIX. Carbodiimide (EDCI) catalyzed coupling of XIX and a suitable amine gives amide XX.

METHOD D

Indole I can be converted to XXI in two steps: (1) reduction with LAH in a solvent such as THF and (2) silylation with t-butyldimethylsilyl chloride (TBDMSCl) in a solvent such as dichloromethane or DMF in the presence of a base such as imidazole. Treatment of XXI with Grignard reagent such as ethyl magnesium bromide in a solvent such as THF at -60 °C, acylation of the resulting magnesium salt with a suitable acyl chloride such as acetyl chloride in ether and finally, alkylation on the nitrogen with an alkyl halide such as ethyl bromide in the presence of a strong base such as NaH in DMF affords ketone XXII. The silyl group on XXII is removed using tetrabutylammonium fluoride in a solvent such THF, the resulting alcohol is then converted to bromide using carbon tetrabromide and bis(diphenylphosphino)ethane in a solvent such as dichloromethane to yield bromide

XXIII. Displacement of the bromine of XXIII with a thiol compound in the presence of a base such as Cs_2CO_3 , or with an alcohol in the presence of a strong base such as NaH in DMF affords XXIV (sulfide, or ether respectively).

5

METHOD E

Aldehyde II, prepared by Method A, can be alkylated by a suitable alkyl bromide (or iodide), such as benzyl bromide or ethyl iodide in the presence of a strong base such as sodium hydride or KHMDS in a solvent such as DMF to yield XXV. XXV can be converted to an unsaturated acid XXVI by two steps: (1) Wittig reaction with a suitable reagent such as trimethyl phosphonoacetate in the presence of a base such as sodium hydride in a solvent such as THF and (2) Hydrolysis by aqueous sodium hydroxide. Coupling reaction of XXVI with an amine catalyzed by a diimide such as EDCI (dimethylaminopropyl ethylcarbodiimide hydrochloride), followed by hydrolysis with aqueous base such as sodium hydroxide affords XXVII.

15

METHOD F

Indole I is reduced with LAH in a solvent such as THF. A second reduction with sodium cyanoborohydride in a solvent such as acetic acid to yield alcohol XXVIII. Protection of the nitrogen of XXVIII with t-butoxycarbonyl (BOC) using di-t-butylidicarbonate $((\text{BOC})_2\text{O})$ in the presence of a base such as triethylamine affords carbamate XXIX. The hydroxyl group in XXIX is mesylated using mesyl chloride and triethylamine in a solvent such as dichloromethane, and then displaced by either a thiol or an alcohol as described in METHOD D to produce indoline XXX. Deprotection of XXX using trifluoroacetic acid affords XXXI, which is either acylated (acyl chloride, triethylamine, dichloromethane) or alkylated (alkyl halide, K_2CO_3 , DMF) to afford XXXII, or XXXIII respectively.

25

30

METHOD G

Carboxylic acid XXXIV is converted to aldehyde XXXV in two steps: (1) reaction with N,O-dimethylhydroxy amine in the presence of EDCI in a solvent such as

dichloromethane, and (2) reduction with diisobutyl aluminum hydride (DIBAL) in a solvent such as THF. Treatment of XXXV with trimethyl phosphonoacetate in the presence of a strong base such as KHMDS in a solvent such as THF results in the formation of ester XXXVI. Reduction of XXXVI with tin in hydrogen chloride, followed by cyclization in a heated inert solvent such as toluene gives XXXVII. Alkylation on nitrogen of XXXVII under conditions described in METHOD F, and then hydrolysis of the ester with aqueous base such as NaOH affords acid XXXVIII. XXXVIII can be converted to an amide XXXIX by coupling with a suitable amine such as benzylamine in the presence of EDCI.

METHOD H

Aldehyde XXXV, prepared in METHOD G, is subjected to a Wittig reaction using methyl triphenylphosphonium iodide in the presence of a strong base such as KHMDS or NaH in a solvent such as THF to afford alkene XL. Reduction of the nitro group of XL with iron powder in an ammonium chloride solution, followed by treatment with benzyl chloroformate in the presence of a base such as triethyl amine produces carbamate XLI. XLI is treated with iodine in a basic solution such as aqueous NaHCO_3 in THF to yield iodide XLII. Displacement of the iodine on XLII with lithium benzoate in a solvent such as DMF, followed by hydrolysis with NaOH affords alcohol XLIII.

METHOD I

Indoline XXVIII, prepared in METHOD F or METHOD H, can be either acylated by reaction with an acyl chloride in the presence of a base such as triethyl amine or alkylated using alkyl halide in the presence of K_2CO_3 in a solvent such as DMF to produce alcohol XLIV. Treatment of XLIV with mesyl chloride and triethyl amine in a solvent such as dichloromethane, followed by displacement with a thiol such as methyl mercaptoacetate in the presence of a base such as Cs_2CO_3 in a solvent such as acetonitrile yields ester XLV. Hydrolysis of XLV with an aqueous base such as NaOH gives acid XLVI, which can be coupled with an amine catalyzed by a diimide such as EDCI in a solvent such as dichloromethane to afford amide XLVII. XLVII can be alkylated on the amide nitrogen by

treatment with alkyl halide and strong base such as NaH in DMF. Hydrolysis of the resulting amide with aqueous base such as NaOH gives acid XLIX. XLIV can also be directly hydrolyzed with NaOH to a carboxylic acid XLVIII.

5

METHOD J

METHOD J illustrates the synthesis of alpha-substituted aminophenylacetic acid esters. Ester L can be deprotonated with a strong base such as lithium diisobutylamide (LDA) in a solvent such as THF, and subsequently alkylated with an alkyl halide such as methyl iodide to give LI. Reduction of LI to amine LIII can be accomplished using hydrogenation catalyzed by palladium in a solvent such as ethanol. L can be oxidized to alcohol LII using LDA and oxaziridine in a solvent such as THF. Alkylation of LII with an alkylating reagent such as methyl iodide in the presence of a strong base such as NaH in DMF, followed by catalytic hydrogenation in the presence of palladium produces amine LIV.

10
15

METHOD K

METHOD K illustrates the synthesis of substituted aminobenzoic acid esters. Mono-acid LV can be converted to amide LVI by the following steps: (1) reaction with oxalyl chloride in dichloromethane to form acid chloride and (2) treatment with a suitable amine such as dimethyl amine. Reduction of the nitro group to the amine is accomplished with hydrogenation catalyzed by palladium as described in METHOD J. LV can be reduced to alcohol LVIII with hydroborane-THF complex in THF. Protection of the hydroxy group as a silyl ether using TBDMSCl in the presence of imidazole and subsequently, reduction of the nitro group (H_2 / Pd-C) to the amine affords LIX. LVIII can be converted to the secondary alcohol LX in two steps: (1) oxidation with a suitable reagent such as manganese dioxide (MnO_2) in ethyl acetate and (2) addition of a desired Grignard reagent such as methyl magnesium bromide in THF. Oxidation of LX with MnO_2 in THF and reduction of the nitro group (H_2 / Pd-C) produces ketone LXIII. Reduction of LVII (H_2 / Pd-C) yields LXI.

20
25
30

METHOD I

Alcohol LXIV, prepared in METHOD I, can be debenzylated by hydrogenolysis catalyzed by palladium on carbon in a solvent such as ethanol. The resulting alcohol is treated with
5 p-methoxybenzyl chloride in the presence of K_2CO_3 in a solvent such as THF to afford LXV. Alcohol LXV can be transformed into ether or sulfide LXVI by the procedures described in METHOD D. Deprotection of the p-methoxybenzyl group with TFA in a solvent such as dichloromethane, and subsequent alkylation on oxygen with a suitable reagent such as 4-benzylbenzyl bromide in the presence of K_2CO_3 in a solvent such as THF
10 affords LXVII.

EXPERIMENTAL SECTION

The Examples which follow further illustrate the invention. All temperatures set
15 forth in the Examples are in degrees Celsius. All the compounds were characterized by proton magnetic resonance spectra taken on a Varian Gemini 300 spectrometer or equivalent instruments.

EXAMPLE 1

20

2-(2-(1-Phenylmethoxycarbonyl-5-phenylmethoxy)indolyl)methoxybenzoic acidStep 1: 2-(5-Phenylmethoxy)indolyl aldehyde

25 12.3 g (42 mmol) of ethyl 2-(5-phenylmethoxy)indolyl carboxylate was dissolved in 100 mL of THF, to which was added 130 mL (130 mmol) of 1 M solution of lithium aluminum hydride in THF at 0 °C. The reaction was stirred at this temperature for 2 hours and quenched by adding 65 mL of 6 N NaOH solution slowly. The product was extracted with ethyl acetate, and the organic phase was washed with aqueous ammonium chloride.
30 Evaporation of the solvent afforded crude alcohol, which without further purification was dissolved in 400 mL of THF, 52 g of manganese(IV) oxide was added, and the mixture was stirred at room temperature overnight. Removal of manganese oxide by filtration and flash chromatographic purification using 3:1 hexane:ethyl acetate yielded 8.15 g of the title compound.

Step 2: Benzyl (1-(2-formyl-5-phenylmethoxy)indolyl)formate

To a solution of 6.9 g (27.5 mmol) of the aldehyde of step 1 in 140 mL of THF was slowly added 61 mL (30.5 mmol) of 0.5 M solution of potassium bis(trimethylsilyl)amide in toluene at
5 -35 °C. After stirring at this temperature for 10 min, 4.4 mL (29.5 mmol) of benzyl chloroformate was added at -35 °C, and the mixture was then warmed from -35 °C to 0 °C for 3.5 hours. The reaction was quenched by pouring into aqueous ammonium chloride. Aqueous work up and flash chromatography using 12:1 toluene:ethyl acetate afforded 4.8
10 g of the title compound.

Step 3: Benzyl (1-(2-hydroxymethyl-5-phenylmethoxy)indolyl)formate

To a solution of 2.9 g (7.5 mmol) of the aldehyde of step 2 in 40 mL of THF and
15 20 mL of trifluoroethanol was added 760 mg (20 mmol) of sodium borohydride at 0 °C. The mixture was stirred at 0 °C for 30 min and then quenched by adding aqueous ammonium chloride. Flash chromatography using 2:1 hexane-ethyl acetate afforded 2.2 g of the title compound.

Step 4: Benzyl (1-(2-bromomethyl-5-phenylmethoxy)indolyl)formate

To a solution of 2.2 g (5.7 mmol) of the alcohol of step 3 and 2.05 g (5.0 mmol) of 1,3-bis(diphenylphosphino)propane in 60 mL of dichloromethane was added a solution of 2.0 g (6 mmol) of carbon tetrabromide in 4 mL of dichloromethane at 15 °C. The mixture
25 was stirred at room temperature for 2 hours and 1 g (3 mmol) of 1,3-bis(diphenylphosphino)propane was added at room temperature. After 1 hour stirring, the reaction was quenched by adding aqueous ammonium chloride. Aqueous work up and flash chromatography using 4:1 hexane:ethyl acetate afforded 1.7 g of the title compound.

Step 5: Benzyl (1-(2-(2-formylphenoxy)methyl-5-phenylmethoxy)indolyl)formate

To a solution of 439 mg (3.6 mmol) of methyl 2-hydroxybenzoate in 18 mL of THF was added 6 mL (3 mmol) of 0.5 M solution of potassium bis(trimethylsilyl)amide in toluene at 0 °C. The solution was stirred at 0 °C for 10 min, to which was added a solution

of 1.25 g (2.8 mmol) of the bromide, prepared in step 4, in THF at 0 °C. The reaction was warmed to room temperature and stirred at this temperature for 2 hours. After aqueous work up (NH₄Cl / ethyl acetate), the organic solvent was collected, dried over sodium sulfate and evaporated. The product was solidified and washed with ethyl acetate:hexane 1:1. Yield 690 mg (51%).

Step 6:

120 mg (0.24 mmol) of the aldehyde of step 5 was dissolved in 11 mL of 5:1:5 THF-acetonitrile-2,2-dimethylethanol. To this solution was added a solution of 56 mg (0.5 mmol) of sodium chlorite in 0.5 mL water and 1 drop of aqueous hydrogen peroxide solution. After 4 hours, another 56 mg (0.5 mmol) of sodium chlorite was added. The mixture was stirred at room temperature for three days. Aqueous work up and flash chromatography using 2.5:1:0.05 hexane:ethyl acetate:acetic acid afforded 110 mg of the title compound.

EXAMPLE 2

4-(2-(1-Phenylmethoxycarbonyl-5-phenylmethoxy)indolyl)methoxybenzoic acid

The title compound was prepared according to the procedure described in Example 1, but using 4-hydroxybenzaldehyde.

EXAMPLE 3

3-(2-(1-Phenylmethoxycarbonyl-5-phenylmethoxy)indolyl)methoxybenzoic acid

The title compound was prepared according to the procedure described in Example 1, but using 3-hydroxybenzaldehyde.

EXAMPLE 4

Benzyl (1-(2-(2-(1-oxo-2,2,2-trifluoroethyl)phenoxy)methyl-5-phenylmethoxy)indolyl)formate

5

Step 1: Benzyl (1-(2-(2-(1-hydroxy-2,2,2-trifluoroethyl)phenoxy)methyl-5-phenylmethoxy)indolyl)-formate

10 A solution of 0.4 g (0.8 mmol) of the aldehyde, prepared in step 1 of Example 1, in 4 mL of THF was cooled to 0 °C. To this were added 0.24 mL (1.6 mmol) of trifluoromethyl trimethylsilane and 5 mg of tetrabutylammonium fluoride trihydrate. The reaction was stirred for 2.5 hours at 0 °C, and additional 0.2 mL (1.3 mmol) of trifluoromethyl trimethylsilane and 5 mg of tetrabutylammonium fluoride trihydrate were added. After stirred at 0 °C for 2 hours, the reaction was worked up with aqueous
15 ammonium chloride and ethyl acetate. Silica gel chromatographic purification using 4:1 hexane-ethyl acetate afforded corresponding TMS ether. Treatment of TMS ether with 1.3 mL of 1N HCl solution at room temperature, aqueous workup using brine and ethyl acetate and chromatographic purification using 3:1 hexane-ethyl acetate gave 230 mg of the titled compound.

20

Step 2:

To a solution of 150 mg (0.27 mmol) of trifluoroethanol, prepared in step 1, in 5.5 mL of dichloromethane was added 255 mg (0.6 mmol) of the Dess-Martin's periodinate.
25 The mixture was stirred at room temperature for 1 hour, and then partitioned between aqueous NaHCO₃ and ethyl acetate. The organic phase was washed once with aqueous NaHCO₃ and purified with chromatography using 3:1 hexane-ethyl acetate to yield 150 mg of the titled compound.

30

EXAMPLE 53-(2-(1-Benzyl-5-benzyloxy)indolecarboxamido)benzoic acid5 Step 1: Ethyl 2-(1-benzyl-5-benzyloxy)indolecarboxylate

To a solution of 1 g (3.4 mmol) of ethyl 5-benzyloxyindole-2-carboxylate in 12 ml of DMF, sodium hydride (0.163g, 60% oil dispersion, 4.07 mmol) was added at room temperature. The reaction was stirred for 30 minutes. Benzyl bromide (0.44 mL, 3.73
10 mmol) was added at this time and the reaction stirred for another hour. On completion of the reaction (monitored by TLC = 0.5 R_f in 3:1 Hexane:Ethyl acetate) it was quenched with water, extracted with ethyl acetate (3X). Organic layers were dried over magnesium sulfate, concentrated and used for the next step.

15 Step 2: 2-(1-Benzyl-5-benzyloxy)indolecarboxylic acid

The ester (3.4 mmol), prepared in step 2, was dissolved in THF (20 mL), methanol (20 mL) and then 1N NaOH (15 mL) was added. The reaction mixture was stirred at room temperature over night at which time it was concentrated, diluted with water, acidified to
20 pH 5 with 10% HCl and extracted with ethyl acetate (3X), the organic extracts were dried over magnesium sulfate and concentrated to give the indole acid (1.14 g, 94.2 %, TLC = 0.5 R_f in 1:1 Hexane:Ethyl acetate with 1% acetic acid).

25 Step 3: Ethyl 3-(2-(1-benzyl-5-benzyloxy)indolecarboxamido)benzoate

The acid (0.54 g, 1.5 mmol) of step 2, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI) (0.32 g, 1.66 mmol), 4-dimethylaminopyridine (DMAP) (0.018 g, 0.15 mmol) and ethyl 3-aminobenzoate (0.27 g, 1.66 mmol) were stirred in tetrahydrofuran (9 mL) at room temperature overnight. The next day the reaction was
30 diluted with ethyl acetate and water, extracted with ethyl acetate (3X), dried over magnesium sulfate and concentrated. The crude material was purified on silica gel using 3:1 hexane:ethyl acetate to give pure amide (0.578 g, 76%, TLC = 0.4 R_f in 3:1 Hexane:Ethyl acetate).

Step 4:

The ester (0.578 g, 1.15 mmol), prepared in step 3, was dissolved in THF (13.6 mL), methanol (13.6 mL) and then 1N NaOH (9.6 mL) was added. The reaction mixture was stirred at room temperature overnight at which time it was concentrated, diluted with water, acidified to pH 5 with 10% HCl and extracted with ethyl acetate (3X), the organic extracts were dried over magnesium sulfate and concentrated to give the titled compound (0.437 g, 80 %, TLC = 0.5 R_f in 3:1 hexane:ethyl acetate with 1% acetic acid).

The Examples 6, 7, 8, 9, 10 and 11 in Table I were prepared by the procedures of Example 5 using suitable amines and alkyl halides.

EXAMPLE 12

3-(2-(3-(2,4-bis(1,1-dimethylpropyl)phenoxyacetyl)-5-methoxy-1-methyl)indolyl)methylthioacetamido-4-methoxybenzoic acid

Step 1: 2-(5-Methoxy)indolylmethanol

Ethyl 5-methoxy-2-indolcarboxylate (30 g, 102 mmol) is dissolved in 250 mL of THF and cooled to 0° C and Lithium Aluminum Hydride (LAH) (255 mL of a 1.0 M solution in THF) is added via addition funnel over 40 minutes. The reaction was stirred a further 2 hours at 0° C and then worked up by the addition of 4N NaOH (190 mL). The resulting salts are filtered and washed with ethyl acetate (3X400 mL), the filtrates are combined and dried over MgSO₄ and concentrated to yield 24.8 g of alcohol, which was used for the next reaction directly.

Step 2: 2-(5-methoxy)indolylmethoxy-tert-butyldimethylsilane

The crude indole alcohol prepared in step 1 (6.2 g, 32.6 mmol) was dissolved in DMF (10.5 mL). To this solution was added imidazole (5.5g, 81.5 mmol) and t-butyldimethylsilyl chloride (5.4g, 35.8 mmol). The mixture was stirred at room

temperature overnight. The reaction was poured into water and extracted with ethyl acetate (3X). Organic layers were dried over magnesium sulfate and concentrated. The crude material was purified on a silica gel column using 19:1 hexane:ethyl acetate to give pure product (9.5g, 31 mmol, 94 % yield, TLC: 0.8 Rf in toluene:ethyl acetate 2:1)

5

Step 3: 3-(2-tert-butyldimethylsilyloxymethyl-5-methoxy)indolyl (2,4-bis(1,1-dimethylpropyl)phenoxy)methyl ketone

2.32 g (7.95 mmol) of 2,4-Bis-tert-amylphenoxyacetic acid was dissolved in dichloromethane (21 mL), oxalyl chloride (1.4 mL 16.1 mmol) was added, followed by dimethyl formamide (0.5 mL) at room temperature. After one hour the reaction is concentrated and azeotroped with toluene and left on the high vacuum for two hours.

In another reaction vessel, a solution of the silyl protected indole, prepared in step 2, (2 g, 6.56 mmol) in ether (20 mL) was added dropwise to ethyl magnesium bromide (2.4 mL of a 3M solution in ether, 7.2 mmol) in ether (10 mL), the latter maintained at -78 °C. The reaction was stirred at -60°C for 2 hr. To this reaction solution, the above prepared acid chloride in ether (4 mL) was added slowly. The reaction was maintained between -50°C and -60°C for another 2 hrs. The reaction was then quenched with saturated sodium bicarbonate. Extracted with ethyl acetate (3X). Organic layers were dried over magnesium sulfate and concentrated. The crude material was purified on a silica gel column using 19:1 Hexane:Ethyl acetate to give pure product (2.36 g, 50%, TLC: 0.15 Rf in hexane:ethyl acetate 19:1).

Step 4: 3-(2-tert-butyldimethylsilyloxymethyl-5-methoxy-1-methyl)indolyl (2,4-bis(1,1-dimethylpropyl)phenoxy)methyl ketone

To the ketone (1.97g, 3.4 mmol) of in step 3 in 12 mL of DMF, sodium hydride (0.163g, 60% oil dispersion, 4.07 mmol) was added at room temperature. The reaction was stirred for 30 minutes. Methyl iodide (0.23 mL, 3.73 mmol) was added at this time and the reaction stirred for another hour. On completion of the reaction (monitored by TLC) it was quenched with water, extracted with ethyl acetate (3X). Organic layers were dried over magnesium sulfate, concentrated and the crude product was used for the next step.

Step 5: 3-(2-Hydroxymethyl-5-methoxy-1-methyl)indolyl (bis-2,4-(1,1-dimethylpropyl)phenoxy)methyl ketone

5 A mixture of N-methyl indole, prepared in step 4, (2.01 g, 3.4 mmol) and tetra-butyl ammoniumfluoride (TBAF) (8.5 mL of a 1M solution in THF, 8.5 mmol) in THF (17.9 mL) were stirred at room temperature for one hour. At this time the reaction was diluted with ethyl acetate and water, extracted with ethyl acetate (3X), dried over magnesium sulfate and concentrated. The crude material was purified on silica gel using hexane:ethyl acetate 2:1 to yield pure alcohol (0.82 g, 60 %, TLC: 0.3 Rf in 2:1
10 hexane:ethyl acetate).

Step 6: Methyl 3-(2-(3-(2,4-bis(1,1-dimethylpropyl)phenoxy)acetyl-5-methoxy-1-methylindolyl)methylthioacetamido)-4-methoxybenzoate

15 The indole alcohol, prepared in step 5, (0.20 g, 0.43 mmol) was dissolved in dichloromethane (0.7 mL) and treated with triethylamine (0.1 mL, 0.64 mmol) and cooled to 0° C at which time mesyl chloride (0.04 mL 0.52 mmol) was added over 5 minutes, followed by addition of two drops of DMF. The reaction was stirred for a further 2 hour at 0°C, it was then concentrated and used directly for the next reaction.

20 The above prepared mesylate was dissolved in DMF (0.8 mL). The solution was degassed by bubbling nitrogen through for ten min. Cesium carbonate (0.25 g, 1.29 mmol) was added and then thiol (0.11 g, 0.43 mmol), prepared in Intermediate 1, was added. The mixture was stirred overnight, then poured into saturated ammonium chloride and extracted with ethyl acetate (3X), dried, concentrated. The crude material was purified on a silica gel
25 column using hexane:ethyl = 2:1 acetate to give pure product (0.12 g, 40%, TLC: 0.3 Rf in hexane:ethyl acetate 1:1).

Step 7:

30 The ester, prepared in step 6, (0.12 g, 0.17 mmol) was dissolved in THF (1.0 mL), methanol (1.0 mL) and then 1N NaOH (0.4 mL) was added. The reaction mixture was stirred at room temperature overnight at which time it was concentrated, diluted with water, acidified to pH 5 with 10% HCl and extracted with ethyl acetate (3X), the organic

extracts were dried over magnesium sulfate and concentrated to give the titled compound (85 mg, 72 %, TLC = 0.3 Rf in 1:1 Hexane:Ethyl acetate with 1% acetic acid).

- 5 EXAMPLES 13, 14, 15 and 16 in Table I were prepared by the procedures of Example 12 using Ethyl 2-(5-benzyloxy)indolecarboxylate, acetyl chlorides and suitable alkyl halides.

10 EXAMPLE 17

3-(2-(-5-benzyloxy-1-(2,4-bis(1,1-dimethyl)propyl)phenoxyacetyl)indolinyloxy)methylthioacetamidobenzoic acid

Step 1: 2-(5-Benzyloxy)indolinyloxy-methanol

- 15 Ethyl 5-benzyloxy-2-indolecarboxylate (30 g, 102 mmol) was dissolved in 250 mL of THF and cooled to 0° C, to which Lithium Aluminum Hydride (LAH) (255 mL of a 1.0 M solution in THF) was added via addition funnel over 40 minutes. The reaction was stirred for 2 hours at 0 °C and then worked up by the addition of 4N NaOH (190 mL). The resulting salts were filtered and washed with ethyl acetate (3X400 mL), the filtrates were
20 combined, dried over MgSO₄ and concentrated to yield 24.8 g. This crude material was then dissolved in glacial acetic acid (260 mL) and the resulting yellow solution was cooled to 15° C, sodium cyanoborohydride (18.5 g, 294 mmol) was added portionwise over 10 minutes, and the resulting mixture was stirred for 3 hours. The reaction was quenched by pouring slowly into 1.5 liters of nearly saturated NaHCO₃, extracted with ethyl acetate
25 (3X), dried over MgSO₄ and concentrated to yield a orange solid (29.6 g).

Step 2: tert-Butyl 1-(5-benzyloxy-2-hydroxymethyl)indolinyloxy-formate

- 25 g (85 mmol) of crude alcohol, prepared in step 1, and 4-dimethylamino pyridine
30 (DMAP) (1.19 g, 9.78 mmol) were dissolved in dichloromethane (180 mL). The solution was cooled to 0° C and then triethylamine (13.6 mL, 98 mmol) was added to it. After 10 minutes of stirring a solution of di-tert-butyl dicarbonate (21.3 mL, 98mmol) dissolved in dichloromethane (20 mL) was added via syringe pump over 2 hours. After 1 hour of stirring the reaction was quenched by the addition of 1/2 saturated NH₄Cl solution and

extracted with CH_2Cl_2 (3X), dried over MgSO_4 and concentrated to yield 36.3 g of a yellow oil, which was purified by column chromatography using a hexane:ethyl acetate gradient of 9:1 to 4:1 to 1:1 to deliver the product (15.25 g, 44%).

5 Step 3: Ethyl 2-(5-benzyloxy-1-tert-butoxycarbonyl)indolinylmethylthioacetate

The carbamate, prepared in step 2, (15.25 g, 43 mmol) was dissolved in dichloromethane (180 mL) and treated with triethylamine (9.0 mL, 64.4 mmol). The solution was cooled to -10°C at which time mesyl chloride (4.3 mL, 56 mmol) was added over 5 minutes. The reaction was stirred for a further 2 hour at -10°C , it was then concentrated and used directly for the next displacement reaction.

The above prepared mesylate was dissolved in DMF (85 mL, degassing the solvent is strongly recommended) cesium carbonate (35 g, 107.3 mmol) was added and then ethyl thioacetate (4.70 mL, 42.9 mmol) was added. The mixture was stirred for 1 day, then poured into 1/2 saturated ammonium chloride and extracted with ethyl acetate (3X), dried, concentrated and chromatographed (hexane:ethyl acetate gradient 10:1 to 4:1) to yield 8.55 g of a yellow oily product.

20 Step 4: 2-(5-Benzyloxy-1-tert-butoxycarbonyl)indolinylmethylthioacetic acid

To a solution of the indoline ester, prepared in step 3, (5g, 11 mmol) in 1M potassium hydroxide in methanol (100 mL), water (10 mL) was added. The reaction was stirred at room temperature for two hours at which time it was diluted with water, acidified to pH 5 with 10% HCl and extracted with ethyl acetate (3X), the organic extracts were dried over magnesium sulfate and concentrated to give the indoline acid (4.5g, 95.5%, TLC = 0.5 Rf in 2:1 hexane:ethyl acetate with 1% acetic acid). The crude material was used for the next step directly.

30 Step 5: Ethyl 3-(2-(5-benzyloxy-1-tert-butoxycarbonyl)indolinylmethylthioacetamidobenzoate

The acid (3g, 7 mmol), prepared in step 4, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (1.6g, 8.4 mmol), 4-dimethylaminopyridine (0.85g, 7 mmol) and ethyl 3-aminobenzoate (1.27 g, 7.7 mmol) were stirred in tetrahydrofuran (43 mL) at room

temperature overnight. On next day the reaction was diluted with ethyl acetate and water, extracted with ethyl acetate (3X), dried over magnesium sulfate and concentrated. The crude material was purified on silica gel using 3:1 hexane:ethyl acetate to give the product (3.4g, 85%, TLC = 0.3 Rf in 3:1 hexane:ethyl acetate).

5

Step 6: Ethyl 3-(2-(5-benzyloxy)indoliny) methylthioacetamidobenzoate

To the indoline (3.4g, 5.9 mmol) of step 5, trifluoroacetic acid (24 mL) was added and the reaction stirred for 1 hour at 0°C. The reaction was quenched by the addition of water and the TFA neutralized by the addition of sodium bicarbonate, the aqueous layer was extracted with ethyl acetate (3X), dried over magnesium sulfate and concentrated. The crude material was purified on silica gel using 2:1 hexane:ethyl acetate to yield product (2.7 g, 96 %, TLC = 0.3 Rf in 2:1 hexane:ethyl acetate).

10

Step 7: Ethyl 3-(2-(5-benzyloxy-1-(2,4-bis(1,1-dimethyl)propyl)phenoxyacetyl)indoliny) methylthioacetamidobenzoate

The 2,4-bis(1,1-dimethylpropyl)phenoxyacetic acid (0.228 g, 0.78 mmol) was dissolved in dichloromethane (2 mL), to which oxalyl chloride (0.14 mL 1.6 mmol) was added followed by dimethyl formamide (0.1 mL) at room temperature. After one hour the reaction is concentrated and azeotroped with toluene and left on the high vacuum for two hours. The indoline ester (0.308 g, 0.65 mmol), prepared in step 6, and 4-dimethylaminopyridine (0.008 g, 0.066 mmol) were dissolved in dichloromethane (1.2 mL) and then the above prepared acid chloride in dichloromethane (0.5mL) was added followed by the addition of triethylamine (0.28mL, 1.95 mmol). The reaction was stirred at room temperature overnight, and then diluted with ethyl acetate and water, extracted with ethyl acetate (3X), dried over magnesium sulfate and concentrated. The crude material was purified on silica gel using 2:1 hexane:ethyl acetate to yield product (0.291 g, 60 %, TLC = 0.4 Rf in 2:1 hexane:ethyl acetate).

25

Step 8:

The ester (0.231 g, 0.31 mmol) of step 7 was dissolved in THF (4.3 mL), methanol (4.3 mL) and than 1N NaOH (3.2 mL) was added. The reaction mixture was stirred at

room temperature overnight at which time it was concentrated, diluted with water, acidified to pH 5 with 10% HCl and extracted with ethyl acetate (3X), the organic extracts were dried over magnesium sulfate and concentrated to give the titled product (0.207 g, 93.2 %, TLC = 0.3 Rf in 2:1 hexane:ethyl acetate with 1.5 % acetic acid).

5

EXAMPLE 18

3-(2-(-5-Benzyloxy-1-(2,4-bis(1,1-dimethyl)propyl)phenoxyacetyl)indoliny)-
10 methylthioacetamido-4-methylbenzoic acid

Step 1: Ethyl 2-(5-benzyloxy)indolinylmethylthioacetate

The N-tert-butoxycarbonyl indoline (3.0 g, 6.6 mmol), prepared in step 3 of
15 Example 17, was added to a flask and cooled to 0 °C. To this reaction mixture trifluoroacetic acid was added (35 mL) and the reaction was stirred for 1 hour at 0 °C and then 1 hour at rt. The reaction was quenched by the addition of water, and the TFA was neutralized by the addition of solid sodium bicarbonate, the aqueous layer was extracted with ethyl acetate (4X) and dried over magnesium sulfate and concentrated to an orange oil
20 (1.85 g, 79%) that was used directly for the next step.

Step 2: Ethyl 2-(5-benzyloxy-1-(2,4-bis(1,1-dimethyl)propyl)phenoxyacetyl)- indolinylmethylthioacetate

25 2,4-Bis(1,1-dimethyl)propylphenoxyacetic acid (2.0g, 6.8 mmol), dichloromethane (15 mL), oxalyl chloride (1.2 mL, 13.6 mmol), dimethylformamide (0.1 mL) were stirred at 0° C for 45 minutes at which time the reaction is concentrated and azeotroped with toluene (1X) and concentrated on the high vac for 2 hours before use. The indoline ester (1.85g, 5.2 mmol), prepared in step1, and 4-dimethylaminopyridine (0.08 g) were
30 dissolved in dichloromethane (15 mL) and then the above generated acid chloride in dichloromethane (5 mL) was added followed by the addition of triethylamine (0.95 mL, 6.8 mmol). The reaction was stirred 16 hours at rt, worked up and concentrated (4.0 g, orange oil), chromatographed using a 9:1 to 6:1 gradient of hexane:ethyl acetate to yield the product (2.5g, 75%) that was used for the next step without further purification.

Step 3: 2-(5-Benzoyloxy-1-(2,4-bis(1,1-dimethyl)propyl)phenoxyacetyl)indoliny)methylthioacetic acid

5 The ester (2.5 g, 3.9 mmol), prepared in step 2, was dissolved in THF (20 mL), methanol (6 mL) and then 1N sodium hydroxide (12 mL) was added. The resulting mixture was stirred 24 hours at which time it was concentrated, diluted with water, acidified to pH 4 with concentrated HCl and extracted with ethyl acetate (4X), the organic extracts were dried over magnesium sulfate, concentrated, and purified via chromatography (3:1 hexane:ethyl acetate with 1% acetic acid) to yield 1.17 g (50%) of the product as
10 white solid.

Step 4: Methyl 3-(2-(5-benzyloxy-1-(2,4-bis(1,1-dimethyl)propyl)phenoxyacetyl)indoliny) methylthioacetamido-4-methylbenzoate

15 The acid (0.20 g, 0.33 mmol), prepared in step 3, EDCI (0.08 g, 0.43 mmol), DMAP (4 mg, 0.03 mmol) and methyl 3-amino-4-hydroxy benzoate (0.06 g, 0.33 mmol) were dissolved in THF (3 mL) and refluxed 16 hours. Aqueous workup with ammonium chloride and ethyl acetate and purification via silica gel chromatography (hexane:ethyl acetate 3:1) yielded 0.13 g (52%) of the product as a white solid.

20

Step 5:

The titled compound was prepared from ester, prepared in step 4, according to the procedure described in step 3.

25

EXAMPLES 17 to 36 in Table 2 were prepared according to the procedures described in either Example 17 or Example 18.

30

EXAMPLE 372-(5-Benzyloxy-1-(3,5-bis(trifluoromethyl)phenoxyacetyl)indolinyl)methylthioacetic acid5 Step 1: 2-(5-Benzyloxy-1-(3,5-bis(trifluoromethyl)phenoxyacetyl)indolinyl)methanol

A 1-L oven-dried round bottom flask fitted with a magnetic stirring bar and equalizing dropping funnel was charged with 17.0 g (59 mmol) of 3,5-bis(trifluoromethyl)phenoxyacetic acid, DMF (5 drops) and anhydrous CH_2Cl_2 (300 mL). Oxalyl chloride (23 mL, 263 mmol) was added dropwise over 10 min. After stirring for 10 2.5 h at room temperature solvent, excess oxalyl chloride were removed in vacuo to afford acid chloride as a white solid. This was used immediately in the next reaction.

A 1-L oven-dried round bottom flask fitted with a magnetic stirring bar and equalizing dropping funnel was charged with 15.3 g (60 mmol) of 2-(5-Benzyloxy)indolinylmethanol, prepared in step 1 of Example 17, DMAP (0.73 g, 6 mmol) and anhydrous CH_2Cl_2 (300 mL). After cooling to 0 °C, a solution of above prepared acid chloride (59 mmol) in anhydrous CH_2Cl_2 (100 mL) was added dropwise, followed by NEt_3 (9 mL, 64.7 mmol). After stirring for 1 h at 0 °C the reaction mixture was washed with 15 saturated NaHCO_3 solution (100 mL), 1 N HCl solution (100 mL) and H_2O (100 mL), dried over Na_2SO_4 and filtered. The solvent was removed in vacuo. Purification by 20 column chromatography in silica gel using 25-40% AcOEt in hexane afforded product as a light yellow solid. Yield 22.0 g (71%).

25 Step 2: Ethyl 2-(5-benzyloxy-1-(3,5-bis(trifluoromethyl)phenoxyacetyl)indolinyl)methylthioacetate

A 500-mL oven-dried round bottom flask fitted with a magnetic stirring bar was charged with alcohol (19.0 g, 36.15 mmol), prepared in step 1, anhydrous CH_2Cl_2 (300 mL), and NEt_3 (7.5 mL, 54.23 mmol). MsCl was added dropwise over 2 min and the 30 reaction mixture was stirred at room temperature for 10 min. The solution was diluted with CH_2Cl_2 (500 mL) and washed with 1N HCl solution (100 mL) and saturated NaHCO_3 solution (100 mL). The CH_2Cl_2 solution was dried over Na_2SO_4 and filtered. The solvent was removed and the mesylate was used in the next step without further purification.

5 A 500-mL oven-dried round bottom flask fitted with a magnetic stirring bar was charged with ethyl thioacetate (4.2 mL, 38.5 mmol), and anhydrous THF (75 mL). After cooling in a dry ice/acetone bath $\text{NaN}(\text{SiMe}_3)_2$ (1 M solution in THF, 50 mL, 50 mmol) was added. After 15 min a solution of above prepared mesylate (21 g, 35 mmol) in anhydrous THF (60 mL) was added. After 15 min the reaction mixture was allowed to warm to room temperature. After stirring at room temperature for 100 min the reaction was heated at reflux for 4 h. The solution was allowed to cool to room temperature. It was diluted with CHCl_3 (500 mL), washed with saturated Na_2CO_3 solution (200 mL) and 1N HCl solution (200 mL). The organic solution was dried over Na_2SO_4 and filtered. The solvent was removed in vacuo. The crude material was purified by column chromatography on silica gel using 15% AcOEt in hexane to afford 13.8 g (63%) of product.

Step 3:

15 A 250-mL round bottom flask fitted with a magnetic stirring bar was charged with ester (12.45 g, 19.8 mmol), prepared in step 2, THF (100 mL), MeOH (33 mL) and H_2O (33 mL). $\text{LiOH}\cdot\text{H}_2\text{O}$ (1.08 g, 25.7 mmol) was added and the reaction mixture was stirred at room temperature for 3 h. The solvents were removed in vacuo. The residue was taken into 1N HCl solution (200 mL) and extracted with AcOEt (2 x 400 mL). The combined extracts were washed with 1 N HCl solution (100 mL), dried over Na_2SO_4 and filtered. The solvent was removed in vacuo to afford the titled compound. Yield 11.9 g (100%).

EXAMPLE 38

5 5-(2-(-5-Benzoyloxy-1-(3,5-
 bis(trifluoromethyl)phenoxyacetyl)indoliny) methylthioacetamido) benzene-1,3-
 dicarboxylic acid

10 Step 1: 5-(2-(-5-Benzoyloxy-1-(3,5-bis(trifluoromethyl)phenoxyacetyl)indoliny)
 methylthioacetamido)benzene-1,3-dicarboxylate

15 A 100-mL oven-dried round bottom flask fitted with a magnetic stirring bar was charged with acid (1.2 g, 2 mmol), prepared in step 3 of Example 37, anhydrous THF (40 mL), EDCI (0.544 g, 2.8 mmol), DMAP (0.024 g, 0.2 mmol), and 5-amino-1,3-benzenedicarboxylic acid (0.46 g, 2.2 mmol). The reaction mixture was heated at reflux until no change was detected by TLC. The solvent was removed in vacuo. The residue was dissolved in CH₂Cl₂ (200 mL), washed with 1 N HCl solution (25 mL), dried over Na₂SO₄ and filtered. The solvent was removed in vacuo. The crude material was purified by column chromatography on silica gel using 1-2% MeOH in CH₂Cl₂ to afford 1.2 g (77%) of product.

20 Step 2:

25 A 25-mL round bottom flask fitted with a magnetic stirring bar was charged with ester (0.6 g, 0.76 mmol), prepared in step 1, THF (7.5 mL), MeOH (2.5 mL) and H₂O (2.5 mL). LiOH·H₂O (0.084 g, 2 mmol) was added, and the reaction mixture was stirred at room temperature for 6 h. The solvents were removed in vacuo. The residue was taken into 1N HCl solution (10 mL) and extracted with AcOEt (2 x 50 mL). The combined extracts were dried over Na₂SO₄ and filtered and removed in vacuo. The crude material was purified by column chromatography on silica gel (eluant: 5% MeOH in CHCl₃ + 0.5-0.7% AcOH) to yield 0.28 g (46%) of the titled compound.

30 EXAMPLES 39, 40, 43 in Table 3 were prepared according to the procedurs described in either Example 38.

EXAMPLE 41

5 5-(2-(-5-Benzoyloxy-1-(3,5-
 bis(trifluoromethyl)phenoxyacetyl)indoliny)l)methylthioacetamido)-3-
 hydroxymethylbenzoic acid

10 Step 1: Methyl 5-(2-(-5-benzoyloxy-1-(3,5-bis(trifluoromethyl)phenoxyacetyl)indoliny)l)
 methylthioacetamido)-3-tert-butyl dimethylsilyloxymethylbenzoate

 This compound was prepared according to the procedure described in step 1 of
 Example 38.

15 Step 2: Methyl 5-(2-(-5-benzoyloxy-1-(3,5-bis(trifluoromethyl)phenoxyacetyl)indoliny)l)
 methylthioacetamido)-3-hydroxymethylbenzoate

20 A 25-mL oven-dried round bottom flask fitted with a magnetic stirring bar was
 charged with silyl protected ester (1.32 g, 1.5 mmol), prepared in step 1, anhydrous THF
 (10 mL), and TBAF (1 M solution in THF, 2.5 mol equiv.). The reaction mixture was
 stirred at room temperature for 3 hours. The solvent was removed in vacuo. The oily
 residue was purified by column chromatography on silica gel using 0-30% AcOEt in
 CH₂Cl₂ to afford 0.94 g (92%) of desired product.

25 Step 3:

 The titled compound was prepared according to the procedure described in step 2
 of Example 38.

30

EXAMPLE 42 in table 3 was prepared according to the procedures described in Example
 41.

EXAMPLE 44

5-(2-(-5-Hydroxy-1-(3,5-bis(trifluoromethyl)phenoxyacetyl)indolinyl)methylthioacetamido) benzene-1,3-dicarboxylic acid

Step 1: 2-(5-Hydroxy-1-(3,5-bis(trifluoromethyl)phenoxyacetyl)indolinyl)methanol

A 500-mL Parr Hydrogenation bottle was charged with 2-(5-Benzyloxy-1-(3,5-bis(trifluoromethyl)phenoxyacetyl)indolinyl)methanol (10 g, 19.1 mmol), prepared in step 1 of Example 37, 5% Pd on carbon (1.0 g), AcOEt (150 mL) and MeOH (100 mL) and subsequently hydrogenated at 50 psi for 18 h. The reaction mixture was filtered through Celite and concentrated in vacuo to afford crude product. This was used in the next step reaction without further purification.

Step 2: 2-(5-(4-Methoxy)benzyloxy-1-(3,5-bis(trifluoromethyl)phenoxyacetyl)indolinyl)methanol

A 1-L oven-dried round bottom flask fitted with a magnetic stirring bar and reflux condenser was charged with alcohol (8.56 g, 19.7 mmol), prepared in step 1, 200 mesh K₂CO₃ (6.53 g, 47.2 mmol), KI (3.91 g, 23.6 mmol) and finally the p-methoxy benzyl chloride (3.2 mL, 23.6 mmol) in 450 mL of anhydrous acetonitrile. The reaction mixture was heated at reflux for 4 h. The reaction mixture was partitioned between AcOEt (500 mL) and H₂O (200 mL). The aqueous layer was extracted with AcOEt (3 x 500 mL). The combined AcOEt extracts were washed with brine (500 mL), dried over Na₂SO₄ and filtered. The solvents were removed in vacuo. Purification of the residue by column chromatography on silica gel (eluant: 40% AcOEt in hexane) afforded desired product. Yield 8.7 g (83%).

Step 3: Methyl 5-(2-(-5-(4-methoxy)benzyloxy-1-(3,5-bis(trifluoromethyl)phenoxyacetyl)indolinyl)methylthioacetamido)benzene-1,3-dicarboxylate

A 100-mL oven-dried round bottom flask fitted with a magnetic stirring bar was charged with alcohol (3.2 g, 5.77 mmol), prepared in step 2, and anhydrous CH₂Cl₂ (44

mL). The reaction mixture was cooled to 0 °C and added anhydrous Et₃N (1.2 mL, 8.61 mmol) followed by MsCl (0.53 mL, 6.84 mmol). The reaction mixture was stirred at 0 °C for 5 min. The reaction mixture was partitioned between CH₂Cl₂ (100 mL) and H₂O (50 mL). The aqueous layer was extracted with CH₂Cl₂ (3 x 100 mL). The combined CH₂Cl₂ extracts were washed with 1 N HCl solution (100 mL), saturated NaHCO₃ solution (100 mL), H₂O (100 mL), brine (100 mL), dried over Na₂SO₄ and filtered. The solvents were removed in vacuo to afford mesylate. This was used in the next step reaction without further purification.

A 100-mL oven-dried round bottom flask fitted with a magnetic stirring bar and reflux condenser was charged with above prepared mesylate (3.60 g, 5.70 mmol), anhydrous Cs₂CO₃ (5.19 g, 15.9 mmol) and anhydrous DMF (20 mL). The reaction solution was passed through N₂ for 15 min. Methyl 5-thioacetamido-1,3-benzenedicarboxylate, prepared in Intermediate 2, was added in one portion and the reaction mixture was heated at 50 °C for 18 h. The reaction mixture was partitioned between AcOEt (500 mL) and H₂O (200 mL). The aqueous layer was extracted with AcOEt (3 x 100 mL). The combined AcOEt extracts were washed with saturated Na₂CO₃ solution (100 mL), H₂O (100 mL), brine (500 mL), dried over Na₂SO₄ and filtered. The solvents were removed in vacuo. Purification of the residue by column chromatography on silica gel (eluant: 5% AcOEt in CH₂Cl₂) afforded product. Yield 2.5 g (53%).

Step 4: Methyl 5-(2-(-5-Hydroxy-1-(3,5-bis(trifluoromethyl)phenoxyacetyl)indoliny))methylthioacetamido)benzene-1,3-dicarboxylate

A 100-mL oven-dried round bottom flask fitted with a magnetic stirring bar was charged with ester (2.60 g, 3.17 mmol), prepared in step 3, and anhydrous CH₂Cl₂ (30 mL). To the reaction mixture was added TFA (25 mL) in several portions over 1 min. The reaction mixture was poured onto 500 mL saturated NaHCO₃ solution and extracted with CH₂Cl₂ (3 x 100 mL). The combined CH₂Cl₂ extracts were washed with saturated Na₂CO₃ solution (200 mL), H₂O (200 mL), brine (500 mL), dried over Na₂SO₄ and filtered. The solvents were removed in vacuo. Purification of the residue by column chromatography on silica gel (eluant: 12.5% - 20% AcOEt in CH₂Cl₂) afforded the product. Yield 1.5 g (68%).

Step 5:

A 25-mL round bottom flask fitted with a magnetic stirring bar was charged with ester (270 mg, 0.40 mmol), prepared in step 4, LiOH hydrate (3.3 equiv.), THF (3.6 mL),
5 MeOH (1.2 mL) and H₂O (1.2 mL). The reaction mixture was heterogeneous with white solid suspended in the solution. After stirring for 4 h, more solvents were added in 3 : 1 : 1 = THF : MeOH : H₂O to make a clear solution. The reaction mixture was stirred at room temperature for 18 h and monitored by TLC. The reaction mixture was acidified with 1 N HCl solution to pH = 2 or with acetic acid to pH = 4 and then partitioned between AcOEt
10 (20 mL) and H₂O (20 mL). The aqueous layer was extracted with AcOEt (3 x 20 mL). The combined AcOEt extracts were washed with H₂O (20 mL), brine (20 mL), dried over Na₂SO₄ and filtered. The solvents were removed in vacuo. Purification of the residue by column chromatography on silica gel followed by recrystallization from acetone / hexane afforded 130 mg of the titled compound (50%).

EXAMPLE 45

5-(2-(5-(3,5-Dibromo)benzyloxy-1-(3,5-bis(trifluoromethyl)phenoxyacetyl)indolinyl) methylthioacetamido)benzene-1,3-dicarboxylic acid
20

Step 1: Methyl 5-(2-(5-(3,5-Dibromo)benzyloxy-1-(3,5-bis(trifluoromethyl)phenoxyacetyl) indolinyl)methylthioacetamido)benzene-1,3-dicarboxylate
25

A 25-mL oven-dried round bottom flask fitted with a magnetic stirring bar and reflux condenser was charged with methyl 5-(2-(5-Hydroxy-1-(3,5-bis(trifluoromethyl)phenoxyacetyl) indolinyl)methylthioacetamido)benzene-1,3-dicarboxylate (0.19 g, 0.27 mmol), prepared in step 4 of Example 4, 200 mesh K₂CO₃ (2.4 equiv.) and 3,5-dibromobenzyl bromide (1.2 equiv.) in 7.5 mL of anhydrous acetonitrile.
30 The reaction mixture was heated at 70 °C for 2 h. The reaction mixture was partitioned between AcOEt (30 mL) and H₂O (20 mL). The aqueous layer was extracted with AcOEt (3 x 30 mL). The combined AcOEt extracts were washed with brine (50 mL), dried over Na₂SO₄ and filtered. The solvents were removed in vacuo. Purification of the residue by

column chromatography on silica gel using 15% EtOAc in dichloromethane afforded 0.20 g of the product (77%).

Step 2:

5

The titled compound was prepared from the ester, prepared in step 1, according to the procedure described in step 5 of Example 44.

10 EXAMPLES 46 to 50 in table 4 were prepared according to the procedures described in Example 44, but using corresponding alkylating reagent.

EXAMPLE 51

15

Methyl 3-(2-(5-benzyloxy-1-(4-benzylbenzoyl)indoliny)l)methylthioacetamido)benzoate

4-Benzylbenzoic acid (0.19g, 0.91 mmol) was dissolved in dichloromethane (2.3 ml), next oxalyl chloride (0.16 mL, 1.82 mmol) was added followed by
20 dimethylformamide (0.5 mL) at room temperature. After one hour the reaction was concentrated and azeotroped with toluene and left on high vacuum for two hours.

Ethyl 3-(2-(5-benzyloxy)indoliny)l)methylthioacetamidobenzoate (0.308 g, 0.65 mmol), prepared in step 6 of Example 17, and 4-dimethylaminopyridine (8 mg, 0.066 mmol) were dissolved in dichloromethane (1.2 mL) and then the above prepared acid
25 chloride in dichloromethane (0.5 mL) was added followed by the addition of triethylamine (0.28 mL, 1.95 mmol). The reaction was stirred at room temperature overnight. The reaction was diluted with ethyl acetate and water, extracted with ethyl acetate (3X), dried over magnesium sulfate and concentrated. The crude material was purified on silica gel using 2:1 hexane:ethyl acetate to yield 0.354 g of the titled product (81.7%, TLC = 0.4 Rf
30 in 2:1 hexane:ethyl acetate).

EXAMPLE 523-(2-(5-Benzyloxy-1-(4-benzylbenzoyl)indolinyl)methylthioacetamido)benzoic acid

5 The ester (0.354 g, 0.53 mmol), prepared in Example 51, was dissolved in THF (5.6 mL), methanol (5.6 mL) and then 1N NaOH (4.2 mL) was added. The reaction mixture was stirred at room temperature overnight at which time it was concentrated, diluted with water, acidified to pH 5 with 10% HCl and extracted with ethyl acetate (3X). The organic extracts were dried over magnesium sulfate and concentrated to give the titled
10 product (0.32 g, 94.4 %, TLC = 0.3 R_f in 2:1 hexane:ethyl acetate with 1.5 % acetic acid).

EXAMPLES 53 to 58 in Table 5 were prepared according to the procedures described in Example 51 and 52.

15

EXAMPLE 593-(2-(5-Benzyloxy-1-(2-naphthoxyacetyl)indolinyl)methylthioacetamido)-4-methoxybenzoic acid
20Step 1: Methyl 3-(2-(5-benzyloxyindolinyl)methylthioacetamido)-4-methoxybenzoate

25 This compound was prepared according to the procedures described in step 6 of Example 17, but with methyl 4-methoxybenzoate.

Step 2: Methyl 3-(2-(5-benzyloxy-1-(2-naphthoxyacetyl)indolinyl)methylthioacetamido)-4-methoxybenzoate

30 The indole ester (0.22 g, 0.45 mmol), prepared in step 1, 2-naphthoxyacetic acid (0.11 g, 0.53 mmol), EDCI (0.10 g, 0.53 mmol) and DMAP (5 mg, 0.04 mmol) were weighed into a flask that was equipped with a condenser, flushed with nitrogen, and then tetrahydrofuran (5 mL) was added and the reaction was brought to reflux for 18 hours; the reaction was diluted with 1/2 saturated ammonium chloride and ethyl acetate, extracted 3X

with ethyl acetate, dried over magnesium sulfate, concentrated to yield (0.30 g, 100% crude) a white solid that was used without purification.

Step 3:

5

The ester (0.12 g, 0.20 mmol), prepared in step 2, was dissolved in THF/ methanol and then 1N sodium hydroxide (0.8 mL) was added and the resulting mixture was stirred 16 hours at RT and a further 5 hours at 45°C, workup yielded 0.12 g of a yellow solid that was purified via preparative TLC (1:1 hexane:ethyl acetate with 1% acetic acid) to yield 10 0.12 g of the titled product (95%).

EXAMPLES 60 to 63 in Table 5 were prepared according to the procedures described either in Example 59 or in Examples 51 and 52.

15

EXAMPLE 64

3-(2-(5-benzyloxy-1-tert-butoxycarbonyl)indolinyl)methylsulfonylacetamidobenzoic acid

20

Step 1: Ethyl 3-(2-(5-benzyloxy-1-tert-butoxycarbonyl)indolinyl)methylsulfonyl acetamidobenzoate

To a solution of Ethyl 3-(2-(5-benzyloxy-1-tert-butoxycarbonyl)indolinyl)methylthioacetamidobenzoate (0.05g, 0.09 mmol), prepared in step 5 of Example 17, in 25 dichloromethane (0.1 mL) at room temperature, m-chloroperbenzoic acid (0.06g of 60% m-cPBA, 0.21 mmol) was added and the reaction stirred overnight. Next day the reaction was quenched with an aqueous solution of sodium bicarbonate, extracted with ethyl acetate (3X), dried over magnesium sulfate and concentrated. The crude sulfone (0.52g, 98%, TLC 30 = 0.3 Rf in 1:1 hexane:ethyl acetate) was used for the next reaction directly.

Step 2:

The titled compound was prepared according to the procedure described in step 3 of Example 59.

5

EXAMPLES 66 and 65 were prepared according to the procedures described in Example 18.

10

EXAMPLE 67

2-(2-(-5-Benzoyloxy-1-(2,4-bis(1,1-dimethyl)propyl)phenoxyacetyl)indoliny)methylthiobenzoic acid

15

Step 1: 5-Benzoyloxy-1-(2,4-bis(1,1-dimethyl)propyl)phenoxyacetyl)-2-hydroxymethylindoline

20

The diisopropylethylamine (3.5 mL, 20.5 mmol), DMAP(0.25 g, 2.05 mmol) and the indoline alcohol (4.53 g, 17.7 mmol), prepared in step 1 of Example 17, were weighed into a flask which was flushed with nitrogen and cooled to 0° C at which time a 0° C solution of di-tert-amylphenoxyacetyl chloride (20.5 mmol) in CH₂Cl₂ (50 mL) was added via cannula. The resulting solution was left to warm to room temperature overnight and then quenched by the addition of 1/2 saturated ammonium chloride and CH₂Cl₂, the

25

solution was extracted with CH₂Cl₂ (3X), the combined layers were dried over magnesium sulfate and concentrated to yield (10.4 g) of a yellow foam that was purified via chromatography using a gradient (hexane:ethyl acetate 7:1 to 3:1 to 1:1) to yield 3.62 g of the product.

30

Step 2: 2-(5-Benzoyloxy-1-(2,4-bis(1,1-dimethyl)propyl)phenoxyacetyl)indoliny)methyl methylsulfonate

To a solution of alcohol (1.2 g, 2.26 mmol) in CH₂Cl₂ (15 mL), prepared in step 1, is added triethylamine (0.44 mL, 3.16 mmol). The solution is brought to -50 °C and then

mesyl chloride (0.23 mL, 2.93 mmol) is added. The mixture is stirred 2 h at -50 °C, quenched with saturated ammonium chloride and allowed to come to rt. The mixture is taken up in CHCl₃ (50 mL), washed with saturated sodium bicarbonate (1 X 10 mL), brine (1 X 10 mL), dried (MgSO₄), filtered and concentrated to afford the product (1.19 g, 86%).

5

Step 3: Methyl 2-(2-(-5-benzyloxy-1-(2,4-bis(1,1-dimethyl)propyl)phenoxyacetyl)indoliny) methylthiobenzoate

To a solution of mesylate (0.54 g, 0.89 mmol), prepared in step 2, in degassed DMF (2 mL) is added CsCO₃ (0.724 g, 2.22 mmol) and methyl thiosalicylate (0.134 mL, 0.98 mmol). The mixture is stirred 4 h, taken up in ethyl acetate (20 mL), washed with brine (3 X 3 mL), dried (MgSO₄), filtered and concentrated. Chromatography (gradient, hexane:ethyl acetate 15:1 to 4:1) afforded 0.53 (86%) of the title compound as a yellow oil.

15 Step 4:

The titled compound was prepared according to the procedure described in step 3 of Example 59.

20

EXAMPLE 68 was prepared according to the procedures described in Example 67.

EXAMPLE 69

25

3-(N-(2-(-5-Benzoyloxy-1-(2,4-bis(1,1-dimethyl)propyl)phenoxyacetyl)indoliny) methylthioethyl)aminobenzoic acid

The titled product was prepared according to the procedures described in step 3 of Example 59, but using Intermediate 15.

30

EXAMPLE 70

3-N-Methyl-(2-(-5-Benzyloxy-1-(2,4-bis(1,1-dimethyl)propyl)phenoxyacetyl)indolinyll)
methylthioacetamido-4-methoxybenzoic acid

5

An oven-dried 100 mL, 3-neck round bottom flask, equipped with a stir bar and nitrogen inlet, was charged with methyl 3-(2-(-5-Benzyloxy-1-(2,4-bis(1,1-dimethyl)propyl)-phenoxyacetyl)indolinyll)methylthioacetamido-4-methoxybenzoate (581 mg, 0.757 mmol), prepared in the synthesis of Example 20 using the procedures described in Example 18, and 10 mL of THF was added via syringe. To the resulting yellow solution was added NaH (60% suspension in mineral oil, 39 mg, 0.975 mmol). The reaction mixture was stirred at 25 °C for 1.5 h to afford a pale suspension. Methyl iodide (161 mg, 1.14 mmol) was added, and the reaction mixture was stirred at 25 °C for 2 days. After chilling to 0 °C, water was added (10 mL), followed by 50 mL of half saturated ammonium chloride, and 100 mL of EtOAc. The layers were separated, and the aqueous phase was extracted once with EtOAc (50 mL). The combined organic phases were dried (sodium sulfate), filtered, and concentrated to afford 0.6 g of crude product as an orange oil. This material was dissolved in 15 mL of THF and 10 mL of methanol, and 7 mL of 1N NaOH solution was added, under nitrogen. After being stirred for 2 h at 25 °C, the reaction mixture was concentrated to dryness on the rotary, and 100 mL of 1N HCl, and 100 mL of EtOAc were added. The layers were separated, and the organic phase was dried (magnesium sulfate), filtered, and concentrated. The crude material obtained (0.565 g) was purified by column chromatography on silica gel (eluant: chloroform to 3% MeOH in chloroform) to afford the titled compound (0.415 g, 70% yield).

15

20

25

EXAMPLE 71 was prepared according to the procedures described in Example 70, but using allyl bromide.

30

EXAMPLE 723-(2-(5-benzyloxy-1-(2-(4-pyridinyl))ethyl)indoliny)methylthioacetamidobenzoic acid

5 Step 1: Ethyl 3-(2-(5-benzyloxy-1-(2-(4-
 pyridinyl)ethyl)indoliny)methylthioacetamidobenzoate

 To a solution of ethyl 3-(2-(5-benzyloxy)indoliny)methylthioacetamidobenzoate
(0.30 g, 0.63 mmol), prepared in step 6 of Example 17, in dichloromethane (3.0 mL) and
10 acetic acid (2.0 mL), 4-vinylpyridine (0.08 mL, 0.75 mmol) was added. The reaction was
 stirred at room temperature overnight. The reaction was quenched with half saturated
 sodium bicarbonate, extracted with ethyl acetate (3X), dried over magnesium sulfate and
 concentrated. The crude material was purified on silica gel using a gradient of 2:1
 hexane:ethyl acetate to 100% ethyl acetate to yield 0.023 g of product (25 %, TLC = 0.7 Rf
15 in ethyl acetate).

Step 2:

 The titled compound was prepared according to the procedure described in step 3
20 of Example 59.

EXAMPLE 73

25 3-(2-(5-benzyloxy-1-(2-naphthyl)methyl)indoliny)methylthioacetamidobenzoic acid

Step 1: Ethyl 3-(2-(5-benzyloxy-1-(2-
 naphthyl)methyl)indoliny)methylthioacetamidobenzoate

30 A mixture of 3-(2-(5-benzyloxy)indoliny)methylthioacetamidobenzoate (0.2g,
 0.42 mmol), prepared in step 6 of Example 17, 2-(bromomethyl)naphthalene (0.1 g, 0.42
 mmol) and potassium carbonate (0.17 g, 1.26 mmol) in N,N-dimethylformamide (2 mL)
 was stirred at room temperature overnight. Next the reaction was diluted with ethyl acetate
 and water, extracted with ethyl acetate (3X), dried over magnesium sulfate and

concentrated. The crude material was purified on silica gel using 2:1 hexane:ethyl acetate to yield 0.22 g of product (85 %, TLC = 0.5 Rf in 2:1 hexane:ethyl acetate).

Step 2:

5

The titled compound was prepared according to the procedure described in step 3 of Example 59.

10 EXAMPLES 74 and 75 in Table 6 were prepared according to the procedures described in Example 73.

EXAMPLE 76

15

2-(2-(-5-Benzoyloxy-1-(2-naphthyl)methyl)indolinyl)methylthiobenzoic acid

Step 1: 2-(2-(-5-Benzoyloxy-1-(1,1-dimethyl)ethoxycarbonyl)indolinyl)methyl
methylsulfonate

20

tert-Butyl 1-(5-benzyloxy-2-hydroxymethyl)indolinylformate (6.72 g, 19 mmol), prepared in step 2 of Example 17, was dissolved in CH₂Cl₂ (80 mL, dried over MgSO₄ before use). The clear yellow solution was cooled in a dry-ice bath. Et₃N (4.0 mL) was then added followed by methanesulfonyl chloride (2.0 mL). The reaction mixture was stirred for 2 h at -40 °C then quenched with H₂O. It was washed with saturated NaHCO₃ (300 mL) and the aqueous layer extracted twice with CH₂Cl₂. The combined CH₂Cl₂ layers were dried over MgSO₄, filtered and evaporated to dryness to give the product (7.30 g, 89.1 % yield), which was used for the next reaction directly.

25

30 Step 2: Methyl 2-(2-(5-Benzoyloxy-1-(1,1-dimethyl)ethoxycarbonyl)indolinyl)methylthio
benzoate

Mesylate (7.2 g, 1.8 mmol), prepared in step 1, was dissolved in DMF (50 mL). The clear light brown solution was degassed by vigorously bubbling with Ar for 30 min.

Cesium carbonate (13.8 g) was added followed by methyl thiosalicylate (2.4 mL). The solution changed to a bright yellow and the suspension was stirred overnight. Methyl thiosalicylate (0.15 mL) was added to complete the reaction and the mixture was stirred overnight. The reaction was then quenched by the addition of saturated NaHCO_3 (400 mL). The mixture was extracted with CH_2Cl_2 (3 x) and the combined CH_2Cl_2 solution was back-washed with H_2O (200 mL). The organic layer was dried over MgSO_4 , filtered and evaporated to dryness to give the product (9.71 g, 99%).

Step 3: Methyl 2-(2-(5-Benzyloxy)indoliny)methylthiobenzoate

10

Ethyl acetate (75 mL, dried over MgSO_4 before use) was charged in a 500 mL round bottom flask. HCl gas was bubbled through and the EtOAc/HCl solution was cooled in an ice bath. Methyl ester (8.4 g), prepared in step 2, was dissolved in EtOAc (25 mL, dried over MgSO_4 before use). This solution was transferred to the HCl/EtOAc solution by syringe. The solution turned to red and was stirred in an ice bath. A white precipitate appeared in 1 h and the solution was stirred overnight to complete the reaction. The solid was collected by filtration, washed with dry EtOAc , suspended in saturated NaHCO_3 (175 mL) and stirred with EtOAc (400 mL). The milky emulsion gradually dissolved and the mixture changed to a clear solution. The layers were separated and the aqueous layer was extracted (2 x) with EtOAc , while the combined EtOAc layers were dried over MgSO_4 , filtered and evaporated to dryness to give the product (6.06 g, 90 % yield).

20

Step 4: Methyl 2-(2-(5-Benzyloxy-1-(4-benzyl)benzyl)indoliny)methylthiobenzoate

25

In a 50 mL round bottom flask, ester (1 g), prepared in step 3, was dissolved in DMF (6 mL). p -Benzylbenzyl bromide was added (1 eq) followed by K_2CO_3 (1 eq). The reaction mixture was stirred overnight at room temperature. To complete the reaction additional p -benzylbenzyl bromide (0.5 eq) was added and the reaction was stirred for another 2 hours. After its completion, the reaction was diluted with H_2O and extracted with EtOAc (2 x). The organic layers were combined and dried over MgSO_4 . The MgSO_4 was filtered and the solvent was evaporated to give an oily material which was dried overnight on high vacuum to give the product (1.59 g, 109 % yield).

30

Step 5:

5 The ester (1.52 g), prepared in step 4, was dissolved in THF (10 mL) in a 50 mL round bottom flask. To it was added NaOH (1 eq, 2N) followed by MeOH (3 mL) and the reaction mixture was stirred overnight. Additional NaOH (0.3 eq) was added to complete the reaction and the mixture was stirred throughout the weekend. Then it was acidified and diluted with H₂O and extracted with EtOAc (2 x). The organic layers were combined and dried over MgSO₄. The MgSO₄ was filtered and the solvent was evaporated and dried on high vacuum to give a crude reddish solid. This solid was dissolved in EtOAc and hexane was added to precipitated the product. The resulting solid was filtered and the impure filter cake was combined with the filtrate and evaporated to dryness. This material was treated with EtOAc and EtOH. The resulting solid was filtered then suspended in EtOH, with stirring and heating at a low temperature. Then it was allowed to cool to room temperature. The suspension was filtered and washed with EtOH to give the titled product (280 mg, 19 % yield).

20 EXAMPLES 77, 78 and 79 in Table 6 were prepared according to the procedures described in Example 76.

EXAMPLE 80

25 4-(1-(5-Benzyloxy-2-(bis-2,4-trifluoromethyl)benzyloxymethyl)indoliny)methylbenzoic acid

Step 1: Methyl 1-(5-Benzyloxy-2-(hydroxymethyl)indoliny)methylbenzoate

30 2-(5-Benzyloxy)indolinylmethanol (3.21 g, 12.6 mmol), prepared in DMF (20 mL), methyl 4-(bromomethyl)benzoate (2.88 g, 14.5 mmol) and potassium carbonate (1.77 g, heated to 125 °C before use) were mixed and stirred at room temperature for 2 h. The reaction was diluted with 100 mL of H₂O and extracted three times with EtOAc. The combined EtOAc layers were evaporated to dryness to give the crude product (5.66 g). The crude material was purified on a silica gel column using hexane:ethyl acetate 3:1 to

2:1. The appropriate fractions were combined, evaporated to dryness and further dried on high vacuum to the product (3.00 g, 64%).

Step 2: Methyl 4-(1-(5-Benzyloxy-2-(bis-2,4-trifluoromethyl)benzyloxymethyl)indolinyloxy)methylbenzoate

Ester (700 mg), prepared in step 1, and bis-(2,4-trifluoromethyl)benzyl bromide (0.35 mL) were dissolved in DMF (5 mL). The resulting clear yellow solution was cooled in an ice bath and then NaH (85 mg) was added in small portions over a period of 5 minutes. The suspension was stirred at 0 °C for 4 h. To complete the reaction, another 0.35 mL of 2,4-bis(trifluoromethyl)-benzyl bromide was added and the stirring was continued for another 3 h 40 min. The reaction was then diluted with H₂O and extracted three times with EtOAc. The combined EtOAc layers were evaporated to give a crude product which was then purified on a silica gel column using hexane:ethyl acetate 8:1. The appropriate fractions were combined and evaporated to dryness to give the product (0.417 g, 38.2 % yield).

Step 3:

The titled compound was prepared according to the procedure described in step 5 of Example 76.

EXAMPLES 81 and 82 in Table 6 were prepared according to the procedures described in Example 80.

EXAMPLE 835-(2-(1-(2,4-Bis(trifluoromethyl)benzyl)indoliny)carboxamido-1,3-benzenedicarboxylic acid

5

Step 1: 2-(1-(2,4-Bis(trifluoromethyl)benzyl)indoliny)carboxylic acid

2-Indoliny)carboxylic acid (0.43 g, 2.6 mmol) was dissolved in DMF (5 mL), placed under N₂, and cooled to 0° C, the sodium hydride (0.26 g of a 60 % dispersion, 6.5 mmol) was added and stirring was continued for 1 hour at this temperature. 2,4-Bis(trifluoromethyl)benzyl bromide (1.22 mL, 6.5 mmol) was next added and the reaction was warmed to room temperature overnight. The reaction was then diluted with 1/2 saturated ammonium chloride/ethyl acetate, the aqueous layer was extracted with ethyl acetate (3X), the organic layers were dried over magnesium sulfate and concentrated. The crude product was purified via chromatography (hexane:ethyl acetate 9:1) to yield 0.96 g of the ester. The resulting ester (0.87 g, 0.1.41 mmol) was dissolved in THF/ methanol and then 1N sodium hydroxide (4.21 mL) was added and the resulting mixture was stirred 2 hours at RT, workup and purification via Chromatography (7:1 hexane:ethyl acetate with 1% acetic acid) yielded 0.58 g of the product.

20

Step 2:

The acid (0.25 g, 0.64 mmol), prepared in step 1, EDCI (0.16 g, 0.83 mmol), DMAP (7 mg, 0.06 mmol) and dimethyl 5-aminoisophthalate (0.16 g, 0.77 mmol) were dissolved in THF (2 mL) and refluxed 16 hours which yielded after aqueous workup 0.33 g of a crude product. The ester (0.29 g, 0.50 mmol) was dissolved in THF/ methanol and then 1N sodium hydroxide (1.5 mL) was added and the resulting mixture was stirred 16 hours at RT, workup and purification via Chromatography (1:1 hexane:ethyl acetate with 1% acetic acid) yielded 0.22 g of the titled compound.

30

EXAMPLE 84N-Methylsulfonyl-2-(1-(2,4-bis(trifluoromethyl)benzyl)indoliny)carboxamide

The acid (0.13 g, 0.32 mmol), prepared in step 1 of Example 83, EDCI (0.07 g, 0.39 mmol), DMAP (4 mg, 0.03 mmol) and methylsulfonamide (0.04 g, 0.39 mmol) were dissolved in THF (5 mL) and refluxed 16 hours which yielded after workup (0.16 g),
5 purification via Chromatography (98:2 dichloromethane:methanol) yielded 0.04 g of the titled compound (29%).

EXAMPLE 85

10

N-Phenylsulfonyl-2-(1-(bis-2,4-trifluoromethyl)benzyl)indoliny)carboxamide

The titled compound was prepared according to the procedure described in Example 84, but using phenylsulfonylamide.

15

EXAMPLE 86

5-(2-(5-Methoxybenzyloxy-1-(2,4-
20 bis(trifluoromethyl)benzyl)indoliny)methylaminocarboxamido-1,3-benzenedicarboxylic acid

Step 1: 2-Trimethylsilyl ethyl 1-(5-benzyloxy-2-hydroxymethyl)indoliny)formate

25 An oven-dried 1 L round bottom flask, equipped with a stir bar was charged with 2-(5-benzyloxy)indoliny)methanol (33.2 g, 130 mmol), prepared in step 1 of Example 17, 2-(trimethylsilyl)ethyl p-nitrophenyl carbonate 36.8 g, 130 mmol), NEt₃ (38 ml, 273 mmol), and 300 mL of anhydrous DMF. The reaction mixture was stirred at 60 °C for 28 hours and at room temperature overnight. The resulting solution was concentrated to
30 dryness in vacuo, and 1 L of CHCl₃ and 200 mL of saturated NaHCO₃ solution were added. The layers were separated, and the organic phase was dried (Na₂SO₄), filtered, and concentrated. The crude material obtained (55.7 g) was purified by column chromatography on silica gel (eluant: 0-5 % MeOH in dichloromethane) to afford product (33.5 g, 60% yield).

Step 2: 2-Trimethylsilylethyl 1-(5-hydroxy-2-hydroxymethyl)indolinyformate

An oven-dried 500 mL Parr pressure flask was charged with the alcohol (30 g, 75 mmol), prepared in step 1, Pd/C (10 %, 2.2 g), 100 mL of MeOH, and 300 mL of EtOAc. After being shaken overnight in a Parr apparatus under H₂ atmosphere (50 psi), the reaction mixture was filtered through Florisil. The filtrate was concentrated to dryness on the rotary. The crude material obtained (24 g) was purified by column chromatography on silica gel (eluant: 0-3 % MeOH in dichloromethane) to afford product (20.9 g, 90% yield).

Step 3: 2-Trimethylsilylethyl 1-(5-(4-methoxy)benzyloxy-2-hydroxymethyl)indolinyformate

An oven-dried 1 L round bottom flask, equipped with a stir bar was charged with the diol (27.1 g, 87.7 mmol), prepared in step 2, 4-methoxybenzyl chloride (Aldrich, 15 mL, 110 mmol), K₂CO₃ (200 mesh, 30.4 g, 220 mmol), KI (Aldrich, 18.3 g, 110 mmol), and 800 mL of anhydrous acetonitrile. The reaction mixture was heated at reflux for 4 h. The solution was allowed to cool to room temperature and water (800 mL) and CHCl₃ (1.5 L) were added. The layers were separated, and the aqueous phase was extracted with CHCl₃ (800 mL). The combined extracts were washed with water (200 mL), dried (Na₂SO₄), filtered, and concentrated. The crude material obtained (45 g) was purified by column chromatography on silica gel (eluant: 20-25 % EtOAc in hexane), and recrystallization from EtOAc/Hexane to afford product (22.2 g, 59% yield).

Step 4: 2-Trimethylsilylethyl 1-(5-(4-methoxy)benzyloxy-2-bromomethyl)indolinyformate

To a solution of 3.0 g (6.4 mmol) of the alcohol, prepared in step 3, in 30 mL of dichloromethane was added 2.53 g (7.6 mmol) of carbon tetrabromide and 3.15 g (7.6 mmol) of 1,3-bis(diphenylphosphino)propane. The reaction was stirred at room temperature for 18 h. The reaction was quenched with saturated aqueous NH₄Cl, and the product was extracted with dichloromethane. The combined organic extracts were washed with brine and dried over MgSO₄. The crude product was purified by flash chromatography using hexane:ethyl acetate 3:2 to afford 1.51 g of the product.

Step 5: 2-Trimethylsilylethyl 1-(5-(4-methoxy)benzyloxy-2-azidomethyl)indolinyloformate

To a solution of 1.4 g (2.6 mmol) of the bromide, prepared in step 4, in 15 mL of dimethylformamide was added 0.51 g (7.9 mmol) of sodium azide. The reaction was heated to 75 °C. and was stirred for 18 h. The reaction was quenched with water, and the product was extracted with ethyl acetate. The combined organic layers were washed with water, brine and dried over MgSO_4 . The crude product was purified by flash chromatography using hexane:ethyl acetate 4:1 to afford 1.08 g of the product.

Step 6: 2-Trimethylsilylethyl 1-(5-(4-methoxy)benzyloxy-2-aminomethyl)indolinyloformate

To a solution of 0.88 g (1.9 mmol) of the azide, prepared in step 5, in 20 mL of ethanol was added 90 mg (10%/wt) of Pd/CaCO_3 . The mixture was placed under atmospheric hydrogen, and was stirred for 18 h. The reaction was then filtered through a pad of celite and the organic phase was concentrated. The crude product was purified by flash chromatography using 10% $\text{MeOH/CH}_2\text{Cl}_2$ to afford 0.717 g of the product.

Step 7: Methyl 5-(2-(5-Methoxybenzyloxy-1-(2-trimethylsilyloxy)ethoxycarbonyl)indolinylo methylaminocarboxamido-1,3-benzenedicarboxylate

To a solution of 0.164 g (0.6 mmol) of triphosgene in 5 mL of dichloromethane was added a solution of 0.31 g (1.5 mmol) of dimethyl-5-aminoisophthalate and 0.39 g (3.0 mmol) of diisopropylethylamine in 20 mL of dichloromethane over a 30 minute period via a syringe pump. The reaction was stirred for 1 h at room temperature following the addition, and then a solution of 0.64 g (1.5 mmol) of the amino, prepared in step 6, in 5 mL of dichloromethane was added in one portion. The reaction was stirred for 2 h, and then quenched with water. The product was extracted with ethyl acetate, and the combined organic layers were washed with water, saturated aqueous NaHCO_3 , brine and dried over MgSO_4 . The crude product was purified by flash chromatography using 10% $\text{MeOH/CH}_2\text{Cl}_2$ to afford 0.78 g of the product.

Step 8: Methyl 5-(2-(5-Methoxybenzyloxy)indolinyl)methylaminocarboxamido-1,3-benzenedicarboxylate

5 To a solution of 0.485 g (0.7 mmol) of the ester, prepared in step 7, in 20 mL of acetonitrile was added 2.2 mL (2.2 mmol) of a 1.0 M tetrabutylammonium fluoride solution in THF. The reaction was stirred at room temperature for 18 h. The reaction was quenched with brine, and the product was extracted with ethyl acetate. The combined organic extracts were washed with saturated aqueous NH_4Cl , brine and dried over MgSO_4 . The crude product was purified by flash chromatography using 5% $\text{MeOH}/\text{CH}_2\text{Cl}_2$ to afford 0.342 g of the product.

Step 9: Methyl 5-(2-(5-Methoxybenzyloxy-1-(bis-2,4-trifluoromethyl)benzyl)indolinyl)methylaminocarboxamido-1,3-benzenedicarboxylate

15 To a solution of 0.15 g (0.3 mmol) of the indoline diester, prepared in step 8, in 5 mL of dimethylformamide was added 0.097 g (0.3 mmol) of 2,4-bis(trifluoromethyl)benzyl bromide and 0.12 g (0.9 mmol) of potassium carbonate. The reaction was stirred at room temperature for 18 h. The reaction was quenched with water, and the product was extracted with ethyl acetate. The combined organic extracts were washed with water, brine and dried over MgSO_4 . The crude product was purified by flash chromatography using hexane:ethyl acetate 1:1 to afford 0.066 g of the product.

Step 10:

25 To a solution of 0.063 g (0.1 mmol) of the diester, prepared in step 9, in 5 mL of tetrahydrofuran was added 0.8 mL (0.8 mmol) of a 1.0 N NaOH solution and 0.5 mL of methanol. The reaction was stirred at room temperature for 18 h. The organic solvents were evaporated, and the resulting solid was suspended in water and acidified to pH 3 with 10% HCl. The product was extracted with ethyl acetate, and the combined organic extracts were washed with water, brine and dried over MgSO_4 . The crude product was purified by flash chromatography using 5% $\text{MeOH}/\text{CH}_2\text{Cl}_2$ to afford 0.049 g of the titled compound.

EXAMPLE 87 was prepared according to the procedure described in Example 86, but using 4-(3,5-bis(trifluoromethyl)phenoxy)methyl)benzyl bromide.

5

INTERMEDIATE 1

10 Methyl 4-methoxy-3-thioacetamidobenzoate

Step 1: Bis(methyl 4-methoxy-3-dithioacetamidobenzoate)

15 A 2-L oven-dried round bottom flask fitted with a magnetic stirring bar was charged with Dithioacetic acid (10.2-15.5 g, 56-85 mmol) and anhydrous CH_2Cl_2 (50 mL). Oxalyl chloride (2.1 mol equiv.) was added dropwise over 10 min. The reaction mixture was stirred at room temperature for 4-5 h. Methyl 4-methoxy-3-amidobenzoate (2.1 mol equiv.) in anhydrous CH_2Cl_2 (300-500 mL) and DMAP (0.1 mol equiv.) were added at room temperature. NEt_3 (4.2 mol equiv.) was added dropwise over 30 min. After stirring
20 overnight at room temperature the reaction mixture was washed with 1 N HCl solution (2 x 300 mL), dried over Na_2SO_4 and filtered. The solvent was removed in vacuo. Purification of the residue by column chromatography on silica gel using hexane:ethyl acetate = 5:1 afford desired product in 56% yield.

25 Step 2:

A 1-L round bottom flask fitted with a magnetic stirring bar was charged with disulfide, prepared in step 1, (15.7-26.3 g, 36.6-57.5 mmol) and PPh_3 (1.1 mol equiv.). The reactants were suspended in dioxane/ H_2O (4/1, 375-500 mL) and concentrated HCl
30 solution (5 drops) was added. The reaction mixture was heated at 40 °C until all disulfide was consumed. Solvents were removed in vacuo. The residue was purified immediately by column chromatography on silica gel using hexane : ethyl acetate 2:1 to afford the titled product in 89% yield.

INTERMEDIATE 2Methyl 5-thioacetamido-1,3-benzenedicarboxylate

- 5 The titled compound was synthesized according to the procedures described in Intermediate 1 using 5-amino-1,3-benzenedicarboxylate.

UINTERMEDIATE 3

10

Methyl 2-(3-amino-4-methoxyphenyl)-2-methoxyacetateStep 1: Methyl 2-(3-nitro-4-methoxyphenyl)acetate

- 15 An oven-dried 2-L, 3-neck round bottom flask, equipped with a mechanical stir motor, a low-temperature thermometer and an equalizing dropping funnel, was charged with acetic anhydride (631 mL) and subsequently cooled to -78 °C. Fuming nitric acid (Baker, 90%, 27 mL) was added dropwise via the dropping funnel protected with a drying tube filled with CaCl₂. After addition was completed, the reaction temperature was
- 20 allowed to warm to 20 °C over 1 h. The reaction mixture was cooled to -78°C again and added 4-methoxyphenylacetic acid (50 g, 0.28 mol) dropwise via the dropping funnel. After stirring at -50 °C for 1 h., the reaction mixture was allowed to warm to -30 °C over 20 min. and then cooled to -50 °C again. The reaction mixture was quenched with H₂O (500 mL) at -50 °C and warmed up to room temperature and stirred for 0.5 h. The reaction
- 25 mixture was partitioned between CH₂Cl₂ (500 mL) and H₂O. The aqueous layer was extracted with CH₂Cl₂ (3 x 500 mL). The combined CH₂Cl₂ extracts were concentrated in vacuo to give a yellow oil. This was added slowly to a 2 M solution of NaOH (2 L) cooled at 0 °C and stirred at room temperature overnight. The reaction mixture was partitioned between CH₂Cl₂ (500 mL) and H₂O. The aqueous layer was extracted with CH₂Cl₂ (3 x
- 30 500 mL). The combined CH₂Cl₂ extracts were stirred with 2 M NaOH solution (1 L) for 1 h. The layers were separated and the organic layer was washed with H₂O (500 mL), brine (500 mL), dried over Na₂SO₄ and filtered. The solvents were removed in vacuo to afford crude product as a light yellow solid (56 g). Purification by recrystallization from MeOH (600 mL) gave product. Yield 48 g (77%).

Step 2: Methyl 2-(3-nitro-4-methoxyphenyl)-2-hydroxyacetate

A 25-mL oven-dried round bottom flask fitted with a magnetic stirring bar was charged with ester (2.3 g, 10 mmol), prepared in step 1, and anhydrous THF (100 mL).
5 The reaction mixture was cooled to -78 °C and a solution of $\text{NaN}(\text{SiMe}_3)_2$ (1.0 M in THF, 12 mL, 12 mmol) was added dropwise over 10 min. After stirring at -78 °C for 30 min., the deep purple solution was added dropwise a solution of racemic camphor sulfonyloxaziridine (3.4 g, 15 mmol), prepared by mixing the commercially available (1S)-(+)-(10-camphorsulfonyl)oxaziridine (1.7 g) and (1R)-(-)-(10-camphorsulfonyl)oxaziridine
10 (1.7 g) in 50 mL THF. After stirring at -78 °C for 30 min., the reaction mixture was quenched with sat. NH_4Cl solution (45 mL) at -78 °C and then allowed to warm to room temperature. The reaction mixture was partitioned between ether (250 mL) and H_2O (50 mL). The aqueous layer was extracted with ether (3 x 250 mL). The combined ether extracts were washed with brine (250 mL), dried over Na_2SO_4 and filtered. The solvents
15 were removed in vacuo. Purification by column chromatography on silica gel (eluant: 50% AcOEt in hexane) afforded desired product. Yield 2.2 g (88%).

Step 3: Methyl 2-(3-nitro-4-methoxyphenyl)-2-methoxyacetate

20 A 10-mL oven-dried round bottom flask fitted with a magnetic stirring bar was charged with alcohol (0.30 g, 1.24 mmol), prepared in step 2, Ag_2O (0.68 g, 3.0 mmol) and toluene (3 mL). To this was added CH_3I (0.36 g, 5.75 mmol) dropwise. The reaction flask was capped tightly and placed into a sonication chamber. The reaction mixture was
25 sonicated for 18 h while stirring at room temperature. The reaction mixture was filtered through Celite and concentrated in vacuo to dryness. The residue was purified by column chromatography on silica gel (eluant: 30% AcOEt in hexane) to afford desired product. Yield 0.26 g (82%).

Step 4:

30

A 100-mL oven-dried round bottom flask fitted with a magnetic stirring bar and a three way adapter, connecting to a hydrogen balloon and a water aspirator was charged with nitro compound (0.7 g, 2.6 mmol), 5% Pd on Carbon (10% by weight) and MeOH (20 mL). The reaction flask was placed under vacuum via the water aspirator and subsequently

filled with H₂. This was repeated three times. The reaction mixture was stirred for 18 hours under positive H₂ pressure until all starting material was reacted. The reaction mixture was filtered through Celite and concentrated in vacuo to dryness. The residue was purified by column chromatography on silica gel using 10% ethyl acetate in dichloromethane to afford the titled compound (0.57 g, 97%)

INTERMEDIATE 4

10 Methyl 2-(3-amino-4-methoxyphenyl)-2-tert-butyl dimethylsilyloxyacetate

A 25-mL oven-dried round bottom flask fitted with a magnetic stirring bar was charged with alcohol (0.30 g, 1.24 mmol), prepared in step 2 of Intermediate 3 and anhydrous CH₂Cl₂ (10 mL). The reaction mixture was cooled to 0 °C and added 2,6-lutidine (dried over NaOH pellet, 0.36 mL, 3.11 mmol) followed by addition of 'BuMe₂SiOTf (0.43 mL, 1.87 mmol) dropwise. After stirring at 0 °C for 30 min., the reaction mixture was partitioned between CH₂Cl₂ (20 mL) and H₂O (15 mL). The aqueous layer was extracted with CH₂Cl₂ (3 x 20 mL). The combined CH₂Cl₂ extracts were washed with brine (20 mL), dried over Na₂SO₄ and filtered. The solvents were removed in vacuo. Purification by column chromatography on silica gel (eluant: 30% AcOEt in hexane) afforded desired product. Yield 0.42 g (95%).

Step 2:

25 The titled compound was prepared from nitro compound of step 1 according to the procedure described in step 4 of Intermediate 3.

INTERMEDIATE 5

30

Methyl 2-(3-amino-4-methoxyphenyl)acetate

The titled compound was prepared from nitro compound, prepared in step 1 of Intermediate 3, according to the procedure described in step 4 of Intermediate 3.

INTERMEDIATE 6Methyl 2-(3-amino-4-methoxyphenyl)-2-methylacetate

5

Step 1: Methyl 2-(3-nitro-4-methoxyphenyl)-2-methylacetate

A 25-mL oven-dried round bottom flask fitted with a magnetic stirring bar was charged with redistilled diisopropylamine (0.84 mL, 6.0 mmol) and anhydrous THF (10 mL) and cooled to 0 °C. A solution of n-BuLi (2.5 M in hexane, 2.4 mL, 6.0 mmol) was added dropwise over 5 min. After stirring at 0 °C for 15 min., the reaction temperature was allowed to cool to -78 °C and added a solution of ester (1.13 g, 5.0 mmol), prepared in step 1 of Intermediate 3, in 10 mL THF dropwise. After stirring at -78 °C for 45 min., dimethylsulfate (1.60 g, 12.5 mmol) was added dropwise and the reaction mixture was allowed to warm to room temperature and stirred overnight. The reaction mixture was partitioned between CH₂Cl₂ (50 mL) and H₂O (50 mL). The aqueous layer was extracted with CH₂Cl₂ (3 x 50 mL). The combined CH₂Cl₂ extracts were washed with brine (50 mL), dried over Na₂SO₄ and filtered. The solvents were removed in vacuo. Purification by column chromatography on silica gel (eluant: 30% AcOEt in hexane) afforded 0.7 g of product (58%).

Step 2:

The titled compound was prepared from nitro compound, prepared in step 1, according to the procedure described in step 4 of Intermediate 3.

INTERMEDIATE 7Methyl 2-(3-amino-4-methoxyphenyl)-2-allylacetate5 Step 1: Methyl 2-(3-nitro-4-methoxyphenyl)-2-allylacetate

This compound was synthesized from ester, prepared in step 1 of Intermediate 3, according to the procedure described in step 1 of Intermediate 6, but using allyl bromide.

10 Step 2:

A 25-mL oven-dried round bottom flask fitted with a magnetic stirring bar was charged with ester (0.30 g, 1.13 mmol), prepared in step 1, $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ (1.28 g, 5.66 mmol) and EtOH (5 mL). The reaction mixture was heated at 70 °C for 30 min. The
15 reaction mixture was cooled to room temperature and poured onto ice/water (20 mL) and basified with saturated Na_2CO_3 solution to pH = 8. AcOEt (50 mL) was added. The resulting emulsion was filtered through Celite. The filtrate was partitioned between AcOEt (20 mL) and H_2O (15 mL). The aqueous layer was extracted with AcOEt (3 x 50 mL). The combined AcOEt extracts were washed with brine (50 mL), dried over Na_2SO_4 and
20 filtered. The solvents were removed in vacuo. Purification of the residue by column chromatography on silica gel (eluant: 10% AcOEt in CH_2Cl_2) afforded the titled compound. Yield 0.16 g (60%).

25 INTERMEDIATE 82,4-Bis(1,1-dimethylpropyl)phenoxyacetic acid

The 2,4-bis(1,1-dimethylpropyl)phenol (12 g, 51.2 mmol) in dimethylformamide
30 (100 mL) was cooled to -30° C, treated with solid potassium bis(trimethylsilyl)amide (12.3g, 61.5 mmol), stirred for 30 minutes and then methyl bromoacetate (5.7 mL, 61.5 mmol) was added, the reaction was stirred 1 hour at this temperature and five hours after removal of the cooling bath, workup yielded (16.6g, ≈ 100%) a yellow oil. The oil was dissolved in THF/methanol and treated with 1N sodium hydroxide (155 mL) and stirred for

48 hours. The reaction was concentrated, diluted with water, acidified to pH 4 with concentrated HCl, extracted with ethyl acetate (4X), dried over magnesium sulfate and concentrated. Crystalization from ethyl acetate and hexane yielded 12.85 g of the titled compound. (86%).

5

INTERMEDIATE 9

4-Benzylphenoxyacetic acid

10

The titled compound was prepared from 4-benzylphenol according to the procedure described in of Intermediate 8.

15

INTERMEDIATE 10

2-Naphthoxyacetic acid

The titled compound was prepared from 2-naphthol according to the procedure described in of Intermediate 8.

20

INTERMEDIATE 11

3,5-Bis(trifluoromethyl)phenoxyacetic acid

25

The titled compound was prepared from 3,5-bis(trifluoromethyl)phenol according to the procedure described in of Intermediate 8.

30

INTERMEDIATE 12

Methyl 5-amino-3-(N,N-dimethyl)carbamoylbenzoate

Step 1: Methyl 5-nitro-3-(N,N-dimethyl)carbamoylbenzoate

5 A 100-mL oven-dried round bottom flask fitted with a magnetic stirring bar was charged with 5-nitro-3-methoxycarbonylbenzoic acid (3.15 g, 10 mmol), DMF (1 drop), anhydrous CH_2Cl_2 (70 mL), and oxalyl chloride (3.7 mL, 42.3 mmol). The reaction mixture was stirred at room temperature for 2 h. The solvent was removed in vacuo to afford acid chloride as a white solid. This was used immediately in the next step without further purification.

10 An oven-dried round bottom flask fitted with a magnetic stirring bar was charged with above prepared acid chloride (14 mmol), anhydrous CH_2Cl_2 (50 mL), and dimethylamine hydrochloride (70 mmol). NEt_3 (2 mL, 144 mmol) was added dropwise. After stirring at room temperature for 30-60 min excess NEt_3 (1 mL, 72 mmol) was added and stirring was continued. After 30-60 min the solution was washed with saturated Na_2CO_3 solution (2 x 20 mL), dried over Na_2SO_4 and filtered. The solvent was removed in vacuo to afford 3.3 g of product. This was used in the next step without further purification.

15

Step 2:

20 The titled compound was prepared from nitro compound, prepared in step 1, according to the procedure described in step 4 of Intermediate 3.

INTERMEDIATE 13

Methyl 5-amino-3-acetylbenzoate

25

Step 1: Methyl 5-nitro-3-acetylbenzoate

30 A 250-mL oven-dried round bottom flask fitted with a magnetic stirring bar was charged with di-tert-butyl malonate (2.16 g, 10 mmol), anhydrous toluene (50 mL), and NaH (60% suspension in mineral oil, 0.88 g, 22 mmol). The reaction mixture was heated at 80 °C for 1 h. A solution of methyl 5-nitro-3-chloroformylbenzoate (10 mmol), prepared in step 1 of Intermediate 12, in anhydrous toluene (20 mL) was added and heating was continued for 2 h. The reaction mixture was cooled to room temperature and p-toluenesulfonic acid (0.21 g, 1.2 mmol) was added. The resulting mixture was filtered and

the oily residue was washed with toluene until a white solid was left. The filtrates were combined and the solvent was removed in vacuo. The resulting oil was dissolved in anhydrous toluene (50 mL) and p-toluenesulfonic acid (0.3 g, 1.74 mmol) was added. After heating to reflux for 18 h the reaction mixture was allowed to cool to room temperature, washed with saturated Na_2CO_3 solution (2 x 25 mL), dried over Na_2SO_4 and filtered. The solvent was removed in vacuo. The crude material was purified by column chromatography on silica gel (eluant: CH_2Cl_2) to afford product. Yield 1.06 g (50%).

Step 2:

The titled compound was prepared from nitro compound, prepared in step 1, according to the procedure described in step 4 of Intermediate 3.

INTERMEDIATE 14

Methyl 5-amino-3-(1-tert-butyldimethylsilyloxy)ethylbenzoate

Step 1: Methyl 5-nitro-3-(1-hydroxy)ethylbenzoate

An oven-dried round bottom flask fitted with a magnetic stirring bar was charged with compound methyl 5-nitro-3-acetylbenzoate (0.5 g), prepared in step 1 of Intermediate 13, BH_3 THF (1 M solution in THF, 5 mol equiv.), and anhydrous THF. After stirring at room temperature for 24 h, H_2O (20 mL) was added and the solution was concentrated in vacuo. The residue was taken in H_2O (20 mL) and extracted with CHCl_3 (3 x 100 mL). The combined CHCl_3 extracts were washed with saturated Na_2CO_3 solution (20 mL), dried over Na_2SO_4 and filtered. The solvent was removed in vacuo to afford product. This was used in the next step without further purification.

Step 2: Methyl 5nitro-3-(1-tert-butyldimethylsilyloxy)ethylbenzoate

An oven-dried round bottom flask fitted with a magnetic stirring bar was charged with alcohol (0.5g, 5 mmol), prepared in step 1, tert-BuMe₂SiCl (1.3 mol equiv.), imidazole (2.15 mol equiv.), and anhydrous THF. After stirring at room temperature for

28 hours the solvent was removed in vacuo. The residue was taken in H₂O (50 mL) and extracted with CHCl₃ (2 x 100 mL). The combined CHCl₃ extracts were washed with H₂O (50 mL), dried over Na₂SO₄ and filtered. The solvent was removed in vacuo. The crude material was purified on silica gel using 25%-50% dichloromethane in hexane to afford the product (0.69 g, 91%).

Step 3:

The titled compound was prepared from nitro compound, prepared in step 2, according to the procedure described in step 4 of Intermediate 3.

INTERMEDIATE 15

Methyl 4-methoxy-3-(2-thioethyl)aminobenzoate

Step 1: Bis(2-bromoethyl)disulfide

The dithioethanol (0.79 mL, 6.48 mmol), carbon tetrabromide (4.3 g, 13.0 mmol) and 1,3 bis(diphenylphosphino)propane (5.34 g, 13.0 mmol) were weighed into a flask and flushed with nitrogen and then taken up in CH₂Cl₂ (15 mL) and stirred for 16 hours. workup consisted of pouring into 1/2 saturated ammonium chloride and extracted with CH₂Cl₂ (3X) dry magnesium sulfate and concentrated to yield (9.0 g) of a crude product that was chromatographed (Hexane:Ethyl acetate 9:1) to yield 1.49 g of product.

Step 2: Bis-(methyl 4-methoxy-3-(2-dithioethyl)aminobenzoate

Bromide (0.39 mg, 1.387 mmol), prepared in step 1, and methyl 3-amino-4-methoxy benzoate (1.00 g, 5.51 mmol) were added into a flask, flush with nitrogen and take up in DMF (5 mL) and then heat to 60 ° C for 24 hours at which time the reaction was diluted with ethyl acetate and quenched into water, extracted with ethyl acetate (3X), the combined organic layers were washed with water (3X), dried and concentrated to yield 1.27 g of a product that was purified by chromatography (hexane:ethyl acetate 5:1 to 3:1) to yield 0.15 g of the desired product.

Step 3:

The disulfide (0.15 g, 0.24 mmol), prepared in step 2, and the triphenylphosphine (0.14 g, 0.53 mmol) were taken up in THF (3 mL). H₂O (0.3 mL) and two drops of conc. HCl were added and the resulting mixture was stirred at 40 °C for 2 hours, the reaction was diluted with water and ethyl acetate, extracted with ethyl acetate (3 X) and dried over magnesium sulfate to yield 0.27 g of a crude product that was purified by chromatography (hexane:ethyl acetate 9:1 to 6:1) to yield 0.11 g of the titled compound.

10

Example 88Activity Assays(a) Vesicle Assay

1-palmitoyl-2-[¹⁴C] arachidonyl phosphatidylcholine (58 mCi/mmol) (final concentration 6 μM) and 1,2-dioleoylglycerol (final concentration 3 μM) were mixed and dried under a stream of nitrogen. To the lipids was added 50 mM Hepes pH 7.5 (2x final concentration of lipids) and the suspension was sonicated for 3 min. at 4°C. To the suspension was added 50 mM Hepes pH 7.5, 300 mM NaCl, 2 mM DTT, 2 mM CaCl₂ and 2 mg/ml bovine serum albumin (BSA) (Sigma A7511) (1.2x final concentration of lipids). A typical assay consisted of the lipid mixture (85 μl) to which was added consecutively, the inhibitor (5 μl in DMSO) and cPLA₂, 10 ng for an automated system or 1 ng for a manual assay, in 10 μl of the BSA buffer. This assay was conducted by either the manual assay or automated assay protocol described below.

25

(b) Soluble Substrate Assay (LysoPC)

1-[¹⁴C]-palmitoyl-2-hydroxyphosphatidyl-choline (57 mCi/mmol) (final concentration 4.4 μM) was dried under a stream of nitrogen. The lipid was resuspended by vortexing 80 mM Hepes pH 7.5, 1 mM EDTA (1.2 x final concentration). A typical assay consisted of lipid suspension (85 μl) to which was added consecutively the inhibitor (5 μl in DMSO) and cPLA₂, 200 ng in 80 mM Hepes pH 7.5, 2 mM DTT and 1 M EDTA. This assay was conducted by either the manual assay or automated assay protocol described below.

30

(c) Automated Assay

The lipid suspension and inhibitor were pre-incubated for 7 min. at 37°C. Enzyme was added and the incubation was continued for a further 30 mins. The reaction was then quenched by the addition of decane: isopropanol: trifluoroacetic acid (192:8:1 w/v, 150 µl).
5 A portion of the quench layer (50 µl) was passed through a Rainin Spheric-5 silica column (5µ, 30 x 2.1 mm) eluting with heptane:methanol:TFA (97:3:0.1 v/v). The level of [¹⁴C]-arachidonic acid was analyzed by an in-line Radiomatic Flo-One/Beta counter (Packard).

(d) Manual Assay

10 The lipid, inhibitor and enzyme mixture were incubated at 37°C for 30 min. The reaction was quenched by the addition of heptane:isopropanol:0.5M sulfuric acid (105:20:1 v/v, 200 µl). Half of the quench layer was applied to a disposable silica gel column (Whatman SIL, 1 ml) in a vacuum manifold positioned over a scintillation vial. Free [¹⁴C]-arachidonic acid was eluted by the addition of ethyl ether (1 ml). The level of radioactivity
15 was measured by liquid scintillation counter.

(e) PMN Assay

PMNs were isolated using Ficoll-Hypaque according to the manufacturers directions. Red blood cells contaminating the PMNs were removed by hypotonic lysis, and
20 the PMN pellet was washed once, and resuspended in Hanks buffered saline at a concentration of 2×10^6 cells/ml. The cells were preincubated with inhibitors for 15 min at 37°C and then stimulated with 2 µM A23187. When monitoring LTB₄ production as a measure of cPLA₂ inhibition, the reaction was quenched with an equal volume of ice cold phosphate buffered saline. Cells were removed by centrifugation, and the LTB₄ present in
25 the cell supernatant was measured using the LTB₄ scintillation proximity assay provided by Amersham according to the manufacturers directions. In the assays reported in the Tables above, LTB₄ was measured. When monitoring arachidonic acid production, the reaction was quenched with methanol containing D8-arachidonic acid as an internal reference. The lipids were extracted by the method of Bligh et al. ((1959) Can. J. Biochem. Physiol., 37,
30 911-917), and the fatty acid was converted to the pentafluorobenzyl ester and analyzed by GC-MS in a manner similar to that reported by Ramesha and Taylor ((1991) *Anal. Biochem.* 192, 173-180).

(c) Coumarine (PGE₂ Production) Assay

RBL-2H3 cells were routinely cultured as 37°C in a 5% CO₂ atmosphere in minimal essential medium containing nonessential amino acids and 12% fetal calf serum. The day before the experiment, cells were seeded into spinner flasks at 3 x 10⁵ cells/ml and
5 100 ng/ml DNP specific-IgE was added. After 20 hrs, the cells were harvested by centrifugation and washed once in serum-free minimal essential media, and resuspended to 2 x 10⁶ cells/ml in serum free media. The cells were then preincubated with either inhibitor in DMSO (1% v/v) or DMSO (1% v/v) for 15 min at 37°C followed by stimulation with DNP-BSA (300 ng/ml). After 6 min, the cells were removed by centrifugation, and the
10 supernatant was assayed for PGD₂ content in accordance with known methods.

Example 89



Rat Carrageenan-Induced Footpad Edema Test

Each compound was suspended in 0.3ml absolute ethanol, 0.1 ml Tween-80 and
15 2.0 ml Dulbecco's PBS (without calcium or magnesium). To this mixture, 0.1ml 1N NaOH was added. After solution was complete, additional amounts of PBS were added to adjust the concentration to 1 mg/ml. All compounds remained in solution. Compounds were administered i.v. in a volume of 5 ml/kg to male Sprague Dawley rats at the same time that edema was induced by injection of 0.05ml of 1% Type IV carrageenan into the
20 hind footpad. Footpad volume was measured before dosing with compound and 3 hours after dosing with carrageenan.


All patent and literature references cited herein are incorporated as if fully set forth herein.

What is claimed is:

1. A compound having a chemical formula selected from the group consisting of:



and



or a pharmaceutically acceptable salt thereof, wherein:

A is independent of any other group and is selected from the group consisting of $-\text{CH}_2-$ and $-\text{CH}_2-\text{CH}_2-$;

B is independent of any other group and is selected from the group consisting of $-(\text{CH}_2)_n-$, $-(\text{CH}_2\text{O})_n-$, $-(\text{CH}_2\text{S})_n-$, $-(\text{OCH}_2)_n-$, $-(\text{SCH}_2)_n-$, $-(\text{CH}=\text{CH})_n-$, $-(\text{C}\equiv\text{C})_n-$, $-\text{CON}(\text{R}_6)-$, $-\text{N}(\text{R}_6)\text{CO}-$, $-\text{O}-$, $-\text{S}-$ and $-\text{N}(\text{R}_6)-$;

R_1 is independent of any other R group and is selected from the group consisting of $-\text{X}-\text{R}_6$, $-\text{H}$, $-\text{OH}$, halogen, $-\text{CN}$, $-\text{NO}_2$, C_1-C_5 alkyl, alkenyl, alkynyl, aryl and substituted aryl;


R_2 is independent of any other R group and is selected from the group consisting of $-\text{H}$, $-\text{COOH}$, $-\text{COR}_5$, $-\text{CONR}_5\text{R}_6$, $-(\text{CH}_2)_n-\text{W}-(\text{CH}_2)_m-\text{Z}-\text{R}_5$, $-(\text{CH}_2)_n-\text{W}-\text{R}_5$, $-\text{Z}-\text{R}_5$, C_1-C_{10} alkyl, alkenyl and substituted aryl;

R_3 is independent of any other R group and is selected from the group consisting of $-\text{H}$, $-\text{COOH}$, $-\text{COR}_5$, $-\text{CONR}_5\text{R}_6$, $-(\text{CH}_2)_n-\text{W}-(\text{CH}_2)_m-\text{Z}-\text{R}_5$, $-(\text{CH}_2)_n-\text{W}-\text{R}_5$, $-\text{Z}-\text{R}_5$, C_1-C_{10} alkyl, alkenyl and substituted aryl;

R_4 is independent of any other R group and is selected from the group consisting of $-\text{H}$, $-\text{OH}$, $-\text{OR}_6$, $-\text{SR}_6$, $-\text{CN}$, $-\text{COR}_6$, $-\text{NHR}_6$, $-\text{COOH}$, $-\text{CONR}_6\text{R}_7$, $-\text{NO}_2$, $-\text{CONHSO}_2\text{R}_8$, C_1-C_5 alkyl, alkenyl and substituted aryl;

R_5 is independent of any other R group and is selected from the group consisting of $-\text{H}$, $-\text{OH}$, $-\text{O}(\text{CH}_2)_n\text{R}_6$, $-\text{SR}_6$, $-\text{CN}$, $-\text{COR}_6$, $-\text{NHR}_6$, $-\text{COOH}$, $-\text{NO}_2$, $-\text{CONR}_6\text{R}_7$,

-CONHSO₂R₈, C₁-C₅ alkyl, alkenyl, alkynyl, aryl, substituted aryl, -CF₃, -CF₂CF₃ and



R₆ is independent of any other R group and is selected from the group consisting of -H, C₁-C₅ alkyl, alkenyl, alkynyl, aryl and substituted aryl;

R₇ is independent of any other R group and is selected from the group consisting of -H, C₁-C₅ alkyl, alkenyl, alkynyl, aryl and substituted aryl;

R₈ is independent of any other R group and is selected from the group consisting of C₁-C₅ alkyl, aryl and substituted aryl;

R₉ is independent of any other R group and is selected from the group consisting of -H, -OH, a halogen, -CN, -OR₆, -COOH, -CONR₆R₇, tetrazole, -CONHSO₂R₈, -COR₆, -(CH₂)_nCH(OH)R₆ and -(CH₂)_nCHR₆R₅;

R₁₀ is independent of any other R group and is selected from the group consisting of -H, -OH, a halogen, -CN, -OR₆, -COOH, -CONR₆R₇, tetrazole, -CONHSO₂R₈, -COR₆, -(CH₂)_nCH(OH)R₆ and -(CH₂)_nCHR₆R₅;

W is, independently each time used including within the same compound, selected from the group consisting of -O-, -S-, -CH₂-, -CH=CH-, -C≡C- and -N(R₆)-;

X is independent of any other group and is, independently each time used including within the same compound, selected from the group consisting of -O-, -S- and -N(R₆)-;


Z is independent of any other group and is, independently each time used including within the same compound, selected from the group consisting of -CH₂-, -O-, -S-, -N(R₆)-, -CO-, -CON(R₆)- and -N(R₆)CO-;

m is, independently each time used including within the same compound, an integer from 0 to 4; and


n is independent of m and is, independently each time used including within the same compound, an integer from 0 to 4.

2. The compound of claim 1 having phospholipase enzyme inhibiting activity.


3. The compound of claim 1 wherein said compound has the following chemical formula:



4. The compound of claim 1 wherein said compound has the following chemical formula:



5. The compound of claim 1 wherein compound has the following chemical formula:



6. The compound of claim 1 wherein A is $-\text{CH}_2-$ and R_2 is $-(\text{CH}_2)_n-\text{W}-(\text{CH}_2)_m-\text{ZR}_5$
7. The compound of claim 6 wherein n is 1, m is 1, W is $-\text{S}-$ and Z is $-\text{CO}-$.
8. The compound of claim 7 wherein R_5 is $-\text{NHR}_6$.
9. The compound of claim 8 wherein R_6 is a substituted aryl group.
10. The compound of claim 9 wherein said aryl group is substituted with one or more substituents independently selected from the group consisting of a halogen, $-\text{CF}_3$, $-\text{CF}_2\text{CF}_3$, $-(\text{CH}_2)_p\text{COOH}$, $-(\text{CH}_2)_p\text{CH}_3$, $-\text{O}(\text{CH}_2)_p\text{CH}_3$, $-(\text{CH}_2)_p\text{OH}$, $-(\text{CH}_2)_p\text{S}(\text{C}_6\text{H}_5)$,

$-(CH_2)_pCONH_2$ and $-CHR_{11}COOH$, wherein R_{11} is selected from the group consisting of alkyl, alkenyl, alkynyl, $-(CH_2)_pOH$, and $-O(CH_2)_pCH_3$, and wherein p is an integer from 0 to 4.

11. The compound of claim 6 wherein R_1 is selected from the group consisting of $-H$ and $-OCH_2(C_6H_6)$.

12. The compound of claim 6 wherein R_3 is $-COR_5$, R_5 is $-OCH_2R_6$ and R_6 is a substituted aryl group.

13. The compound of claim 12 wherein said aryl group is substituted with one or more substituents selected from the group consisting of $-CF_3$, $-CF_2CF_3$ and $-C(CH_3)_2CH_2CH_3$.

14. A method of inhibiting the phospholipase enzyme activity of an enzyme, comprising administering to a mammalian subject a therapeutically effective amount of a compound of claim 1.

15. A method of treating an inflammatory condition, comprising administering to a mammalian subject a therapeutically effective amount of a compound of claim 1.

16. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

Figure 1

METHOD A





Figure 2

METHOD B



R = alkoxy, benzyloxy, phenoxy, halogen, CN, NO₂, alkyl or aryl

R' = alkyl, benzyl, alkenyl, alkynyl

R'' = halogen, CN, alkyl alkoxy, alkoxycarbonyl, amido, acyl, H, OH

Figure 3

METHOD C





Figure 4

METHOD D



$\text{X} = \text{O}, \text{S}$

$\text{R} =$ alkoxy, benzyloxy, phenoxy, halogen, CN, NO_2 , alkyl or aryl


$\text{R}' =$ alkyl, benzyl, alkenyl, alkynyl

$\text{R}'' =$ alkyl, aryl

$\text{R}''' =$ alkyl, aryl

Figure 5

METHOD E



$n = 0-1$

R = alkoxy, benzyloxy, phenoxy, halogen, CN, NO₂, alkyl or aryl

R' = alkyl, alkenyl


R'' = H, OH, alkoxy, alkyl, alkenyl

R''' = H, OH, halogen, alkoxy, carboxyl, amido, alkyl, NO₂

R'''' = alkyl, alkenyl

Figure 6

METHOD F




R = alkoxy, benzyloxy, phenoxy, halogen, CN, NO_2 , alkyl or aryl

R' , R'' and R''' are independent alkyl, alkenyl, aryl groups

Figure 7

METHOD G




$n = 1 \text{ or } 2$

R = alkoxy, benzyloxy, phenoxy, halogen, CN, NO₂, alkyl or aryl

R' and R'' are independent alkyl, alkenyl, aryl groups

Figure 8

METHOD H



R = alkoxy, benzyloxy, phenoxy, halogen,
CN, NO₂, alkyl or aryl

Figure 9

METHOD I





Figure 10

METHOD J




$\text{R} = \text{H}$, alkoxy, benzyloxy, phenoxy, halogen, CN , NO_2 , alkyl or aryl

$\text{R}' = \text{alkyl}$, alkenyl

$\text{R}'' = \text{alkyl}$, alkenyl

Figure 11
METHOD K



R, R' = independent H, alkyl, or aryl groups

R'' = alkyl, alkenyl aryl

Figure 12

METHOD L





Figure 13

METHOD M



R = alkoxy, benzyloxy, phenoxy, halogen, CN, NO₂, alkyl or aryl

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/14943

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D209/12 A61K31/40 C07D209/42 C07D401/12 C07D209/10
C07D405/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 620 215 A (ELI LILLY AND COMPANY) 19 October 1994 see claims -----	1,2

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

9 December 1997

Date of mailing of the international search report

17. 12. 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, T.x. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Van Bijlen, H

INTERNATIONAL SEARCH REPORT

national application No.
PCT/US 97/14943

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 97/14943

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

Claims Nos.: 1 - 13

because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

The claims 1-13 are so broad that for determining the scope of a meaningful international search due account has been taken of Rule 33.3 PCT; special emphasis was put on the following subject-matter: the significance of the substituent in position 2 as present in the examples, during the international search.

Remark : Although claims 14 and 15 are directed to a method of treatment of the human/animal body , the search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/14943

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 620215 A	19-10-94	AU 676884 B	27-03-97
		AU 5949294 A	20-10-94
		BR 9401482 A	18-10-94
		CA 2121323 A	17-10-94
		CN 1098715 A	15-02-95
		CZ 9400893 A	15-12-94
		FI 941767 A	17-10-94
		HU 70836 A	28-11-95
		JP 7025850 A	27-01-95
		NO 941361 A	17-10-94
		NZ 260298 A	28-05-96
		US 5684034 A	04-11-97
		ZA 9402615 A	16-10-95
